Podcasts about 21a

It's time for TGIF to get a job already!  Here are this months duties:CluelessS 2 ep 13Labor of LoveDinosaurs S 2 ep 8Career opportunities Perfect StrangersS 6 ep 21A catered affairBoy Meets World S 7 ep 13The provider 

Sunday Morning, May 31, 2026Book of Ephesians: Say "YES" to the big "S"? ... Ephesians 5:17-21A message delivered by Richard Fleming

Rodriguez-Solis v. Blanche, No. 24-1937 (4th Cir. May 21, 2026)right to counsel; continuance; prejudice; importance of immigration attorney  Matter of I-B-M-S-, 29 I&N Dec. 628 (BIA 2026)motion to change venue; webex hearing; off the record discussions; IJ bias; IJ as neural arbiter Matter of L-A-D-, 29 I&N Dec 634 (BIA 2026)Mexican mental health; schizophrenia; particularity; social distinction; series of suppositions and speculation for asylum Vasquez-Chavez v. Blanche, No. 25-1306 (1st Cir. May 22, 2026)fear of family; nexus; failure to corroborate; El Salvador United States v. Pimental, No. 24-1910 (1st Cir. May 20, 2026)crime of violence; carjacking in violation of Mass. Gen. Laws ch. 265, § 21A; assault; realistic probability testKurzban Kurzban Tetzeli and Pratt P.A.Immigration, serious injury, and business lawyers serving clients in Florida, California, and all over the world for over 40 years.eimmigration"Immigration law software you'll love to use."get.eimmigration.com/IRP Gonzales & Gonzales Immigration BondsP: (833) 409-9200immigrationbond.com Stafi"Remote staffing solutions for businesses of all sizes"Click me!Want to become a patron?Click here to check out our Patreon Page!CONTACT INFORMATION:Email: kgregg@kktplaw.comFacebook: @immigrationreviewInstagram: @immigrationreviewTwitter: @immreviewAbout your hostCase notesRecent criminal-immigration article (p.18)Featured in San Diego VoyagerSupport the show

John 14:15-21A sermon preached at St Clements, Burnham Overy. 10 May 2026Rev Canon Malcolm Rogers

I. Tell What? II. Tell to Whom? III. Tell by Whose Strength? Scripture Reading: Mark 16 Text: Mark 16:1-8 Psalter Numbers: 96C, 119L, 105B, 21A, 16C

Sunday Morning, March 29, 2026Book of Ephesians: Saints in Supplication for Other Saints ... Ephesians 3:14-21A message delivered by Richard Fleming

Dr Deb Muth 00:03Well, welcome back to Let’s Talk Wellness Now. I am your host, Dr. Deb. And what is the most talked-about peptides in functional medicine? aren’t actually FDA approved. Not because they don’t work, but because no one’s funded the research to prove it yet. The truth is, some of the compounds that dominate wellness forums, BPC-157, TB-500, thymosin beta-4, epitalin, occupy a fascinating space between breakthrough science and unregulated experimentation. In today’s episode, we’re stepping into that grey zone, the world of investigational peptides, to separate mechanism from marketing. I’m going to walk you through the science that actually shows and where it stops, how to evaluate claims when human data don’t yet exist, and the quality, purity, and safety red flags that you need to recognise. Dr Deb Muth 01:06I created it in a previous episode, so go check that one out. And why honesty is the most important prescription in peptide medicine. If you’ve ever wondered whether these research-only peptides are the frontier of healing or the next functional medicine fad, this episode is for you. So grab your cup of tea or coffee, get comfortable, and let’s talk about what it really means to use peptides that are promising but still under investigation. So we’re going to break just for a second here and have a word from our sponsor. It is because of them that we stay on the air. So thank you for this. And we will be right back. Did you know sweating can literally heal your cells? Infrared saunas don’t just relax you. They detox your body, balance hormones, and boost mitochondrial energy. I’m obsessed with my Health Tech sauna. And right now, you can save $500 with my code at healthtechhealth.com slash dr-muth-req-25. Dr. Deb Muth 02:15All right, guys, welcome back. Let’s dive into investigational peptides, the evidence gap. So the following peptides we’re about ready to discuss are extensively in integrative, functional, and regenerative medicine circles. They may have intriguing mechanisms and promising preclinical data. However, they lack FDA approval, and the evidence quality varies dramatically. from interesting preliminary research to essentially no human data at all. And this distinction is really critical for maintaining scientific integrity. So let’s talk about immune-modulating peptides. There’s thymus and alpha-1, and this is an international story on the thymic peptides. Thymusin alpha-1, known as TA1, is marketed internationally as zidaxin. Dr. Deb Muth 03:16It’s a 28-amino acid polypeptide originally isolated from thymusin fraction 5, which was extracted from bovine thymus tissue. Modern production uses synthetic peptide synthesis. The thymus gland is located behind the sternum and is the primary site for T cell maturation, and thymic peptides like TA1 play roles in human system development and regulation. Now, I love thymus peptides. I love thymus glandular products. I’ve used thymus glandular products for decades. Ground-up animal thymus gland is basically what it is. There are a couple of different supplement companies that I’ve used over the years that are amazing with this. And they do a fantastic job, and they really do help to support the immune system. So when thymus peptides came out, it was really exciting because it took the whole idea of thymus support to a new level. Dr. Deb Muth 04:17The mechanism actually behind the thymus in alpha-1 is complex and involves multiple aspects of immune function. At the cellular level, TA1 enhances T cell maturation and differentiation, particularly the development of helper T cells and cytotoxic T cells. It modulates T cell receptor expression and can influence the balance between Th1 cell-mediated immunity and Th2 humoral immunity responses. And it also enhances the natural killer cell activity and modulates dendritic cell function, which are critical for antigen presentation. and initiation of adaptive immune responses. And on the cytokine level, TA1 influences production of interleukin-2, IL-2, interferon gamma, IFN-γ, and interleukin-10, IL-10. Dr. Deb Muth 05:19These create immune modulatory rather than simple immune stimulatory effects. This is a very important distinction because TA1 appears to help balance the immune system rather than simply ramping this up, which theoretically makes it safer in conditions where immune overstimulation would be a problem, such as an autoimmune disease. Hashimoto’s, autoimmune, lupus, Sjogren’s, any of those autoimmune diseases, we don’t want to overstimulate their immune system. So you want to use a product like this that’s non-stimulating. Now, the regulatory status on TA1 is geographically variable and represents one of the challenges in discussing this peptide with patients. It is not FDA-approved in the United States. However, it is approved in several other countries for specific conditions. Dr. Deb Muth 06:19In Italy, it’s approved for the treatment of chronic hepatitis B and hepatitis C. In China, it’s approved for chronic hepatitis B and adjunct immune compromised patients receiving vaccinations or suffering from certain infections. It has an orphan drug designation in the United States for certain cancer indications, but its designation does not constitute approval. It simply provides regulatory incentives for further development. So the evidence base for thymosin alpha-1 is substantial in some areas but comes primarily from non-US populations and research groups, which creates challenges in evaluating quality and generalizable information. So in hepatitis B and C, multiple clinical trials, many conducted in China and Italy, have examined TA1 as an adjunct to antiviral therapy. Dr. Deb Muth 07:21A meta-analysis by Wu and colleagues published in the Journal of Viral Hepatitis in 2013 examined 23 randomized controlled trials, including over 2,000 patients with chronic hepatitis B. The analysis found that combining TA1 with nucleoside analogs like LAMVDUDE or an and TCAVAR improved the hepatitis antigen seroconversion rates by HBV DNA clearance compared to its nucleoside analogs alone. And the effect sizes were modest but statistically significant, with the HBE-AG seroconversion rates improving from about 24% with antivirals alone to 38% in combined therapy. Now in hepatitis C, early trials before the development of direct-acting antivirals showed that TA1 combined with interferon alpha improved sustained virological responses, and compared to interferon alpha, Dr. Deb Muth 08:30Furon alone, particularly in difficult-to-treat populations like those with a genotype one or a high viral load. However, the advent of highly effective direct acting antivirals that achieve SRV rates, sorry, SVR rates exceeding 95%, the role of TA1 in hepatitis C has become less clear. Now in sepsis and critical illness, more recent interest has focused on TA1 in severe cases of sepsis and septic shock. Ren and colleagues published a systematic review and meta-analysis in the Frontiers of Immunology in 2022, analyzing 18 randomized controlled trials, including 1787 patients with severe sepsis or septic shock the pooled analysis showed that ta1 administration was associated with reduced 28-day mortality relative risk at 0.70 meaning a 30 reduction in mortality compared to the standard care alone and the effect appeared Dr. Deb Muth 09:39most pronounced in patients with sepsis-induced immunosuppression measured by HLA-DR expression in monocytes. Now, this is amazing because going forward, we’re going to talk about something that’s commonly known as cytokine storm. Now, cytokine storm really became apparent since 2020 with the viral infection that we’re dealing with in the world today. But they were already looking at this kind of cytokine storm produced by sepsis or sepsis-induced immunosuppression. And it triggered this hyperinflammatory response called the cytokine storm. And many patients who survived the initial phase of the immune suppressed stata, characterized by a T cell exhaustion, reduced antigen presentation, and increased susceptibility to secondary infections. Thymusin alpha-1, TA1, may help restore this immune competence in this phase. However, it’s important to note that patient selection and timing are critical. Dr. Deb Muth 10:43Giving this immune stimulant during a hyperinflammatory phase could theoretically worsen outcomes. So you don’t want to give it to them while they’re in the flare up or the sepsis or the infection, but given to them during the immunosuppression phase afterwards might be beneficial. Now there is also some cancer immunotherapy that we see with TA1 and has been studied as an adjunct in cancer treatment with the hypothesis that it could enhance immune surveillance and response to tumors. And a comprehensive review of Garci and colleagues published in Expert Opinion on Biological Therapy in 2007 examined multiple trials in melanoma, lung cancer, hepatocellular carcinoma, and other malignancies. And the results were mixed. Some trials showed improvement in the immune parameters, increased CD4 in T-cells. improved lymphocyte proliferation responses and some actually showed trends toward improved progression free survival but overall survival benefits were inconsistent and the heterogeneity of the cancer types treatment protocols and outcome measures makes a definitive conclusion difficult as a vaccine adjunct several studies particularly from china have examined ta1 as an adjunct to enhance vaccine responses Dr. Deb Muth 12:11in immune-compromised populations, including the elderly, dialysis patients, and transplant recipients. The rationale is sound. These populations often mount suboptimal antibody responses to vaccines, and TA1’s immune-enhancing effects might improve protection. There are small trials. They have shown improvement in seroconversion rates of hepatitis B vaccines and influenza vaccine in these populations. And though large-scale confirmatory studies are limited, there is a possibility here. Now, on their safety profile, one of the appealing aspects of thymusin alpha-A TA1 is that it’s apparently favorable safety profile in clinical trials. There are some injection site reactions with a little redness, a mild discomfort, and most commonly reported adverse effects. is that their severe adverse events attributable to TA1 have been rare in published trials. However, comprehensive long-term safety data are limited Dr. Deb Muth 13:13And theoretically, concern exists that immune modulation could potentially trigger or exasperate autoimmune conditions in susceptible individuals. Though this hasn’t been clearly demonstrated in clinical trials, integrative medicine considerations for integrative practitioners concerning the thymus and alpha-1, several factors require careful thought. First, sourcing and quality control are critical concerns. Since it’s not FDA approved, TA1 available in the United States typically will come from a compounding pharmacy or an international supplier with variable quality assurance. And pharmaceutical grade product with certificates of analysis showing purity, sterility, and endotoxin testing is essential, but it is readily available from many of these companies. Second, patient selection matters immensely. TA1 should be considered in complex cases where conventional approaches have been insufficient, such as chronic viral infections not responding adequately Dr. Deb Muth 14:21to standard antivirals, post-viral syndromes with evidence of immune dysfunction, cancer patients with immune suppression in consultation with oncology, and it should generally be avoided in active autoimmune disease unless there’s a compelling rationale and close monitoring. Now, TA1 is not a standalone therapy. In cases of chronic viral infection, Comprehensive immune support includes addressing nutritional deficiencies, optimizing vitamin D levels to be between 50 and 80, adequate zinc, selenium, and vitamin A, optimizing gut health since 80% of our immune function is in the gut, you need to optimize gut function. Managing stress from the HPA access dysfunction, chronic cortisol elevation, suppression, and immunity, ensuring adequate sleep, immune memory consolidations during sleep, addressing any metabolic dysfunction, insulin resistance, repairs in the immune function, and the bottom line on thymus and alpha-1 is Dr. Deb Muth 15:26is that it represents legitimate medicine in other countries with a substantial evidence base in specific contexts, but it remains experimental in the U.S., and practitioners using it should provide comprehensive, informed consent about its regulatory status, evidence quality, and source verification. while ensuring it’s part of comprehensive protocols. It is not a magic bullet. And again, what you’re gonna hear me say quite often here is that many of these peptides should be used in conjunction with something else. They should not be used alone. And can peptides be stacked? The answer is yes, they can. So if somebody has an insulin resistance, or a metabolic dysfunction, they can tier TA1 with a GLP-1 like terzepatide or semiglutide. That is not a problem to do that. You need to just work with a practitioner that understands how to do that effectively. So let’s look at BPC-157. Dr. Deb Muth 16:26This is a phenomenon I love BPC-157. Let’s separate it from marketing to actual mechanism of actions here. So BPC-157 stands for Body Protection Compound 157. It is a chain of 15 amino acids that are described as a partial sequence of body protection compound, a protein found in human gastric juice. It has become one of the most hyped peptides in regenerative medicine inside the athletic performance and biohacking communities with claims ranging from healing tendons and ligaments to repairing gut lining or reversing organ damage. The challenge is separating the legitimate mechanisms of science from the marketing hype. The proposed mechanism of BPC-157 are biologically plausible and intriguing. The research suggests that it may influence several growth factor pathways, including vascular endothelial growth factor, VEGF, which promotes new blood vessel formation and has improved better supply of blood flow to injured tissues, theoretically accelerating healing. Dr. Deb Muth 17:40It may also affect fibrous blast growth factor, FGF, and transforming growth factor beta, TGF beta pathways. both involved in tissue repair and remodeling. And some studies actually suggest that BPC-157 modulates inflammatory cascades, potentially reducing excessive inflammation while promoting the resolution phase that allows tissue rebuilding. Now I want to talk just a few moments here about these different tests that we’re talking about tgf beta veg f for those of you who are in our mold world you are very familiar with these uh lab tests we do this to see if you have a mold exposure what’s happening to your body and it’s been very challenging to try to heal this part of the mold illness and manipulate these VEGFs and TGF betas. And so with the fact that BPC helps us modulate this inflammatory cascade, BPC can be very helpful in the world of mold or mycotoxin illness in repairing those parts of the body that have been damaged by the mycotoxins. Dr. Deb Muth 18:48Now there is animal research on BPC-157. It is extensive and primarily from a research group led by pre-drag, oh, I can never say these names, Cyrek at the University of Zagreb in Croatia. Published studies in animal models have shown accelerated healing in a remarkable variety of injury types. A 2011 paper by Chang and colleagues in the Journal of Applied Physiology demonstrated that BPC-157 improved therapy tendon healing in rats with Achilles tendon injuries, and the treated rats showed increased tendon outgrowth, better cell survival in the injured area, enhanced cell migration to the injury site, and improved biochemical strength of the healed tendon compared to controls. Multiple other animal studies have shown similar promising effects. Ligament tears, healing faster in rabbits, muscle damage recovering more quickly in rodent models, gastric ulcers healing in rats given experimental induced ulcerations, inflammatory bowel lesions improving in mouse models of colitis, and even bone to tendon healing showing enhancement in animal studies. Dr. Deb Muth 20:02The breadth of injury types showing benefit in preclinical models explains the enthusiasm of this peptide. However, this is critical. These animal studies, primarily in rodents and rabbits, animal models of injury healing don’t reliably translate to human clinical outcomes. And the doses used in these animal studies when converted to human equivalent doses vary widely. And optimal human dosing is completely unknown at this point. it is all considered experimental and perhaps most importantly there are essentially no peer-reviewed controlled clinical trials in human published in humans published in major medical journals in a 2001 review of arthroscopy and the journal of arthroscopic and related surgery specifically examined in the evidence of bpc 157 and other peptides in musculoskeletal medicine The authors concluded bluntly that BPC-157 lacks evidence from randomized controlled trials and has an unknown safety profile in humans. Dr. Deb Muth 21:09 They emphasized that the jump from animal data to recommending peptides for humans use bypasses the fundamental requirement for Phase I safety studies, Phase II dose-finding studies, and Phase III efficacy trials that would establish whether BPC-157 actually works in humans and whether or not it’s safe. The absence of human safety data is particularly concerning given BPC-157’s proposed mechanisms. Peptides that influence growth factor signaling and angiogenesis could theoretically have off-target effects. Uncontrolled angiogenesis, for instance, is a hallmark of cancer progression. Tumors require blood vessel formation to grow beyond a certain size. And while there’s no evidence that BPC 157 promotes cancer, The complete absence of long term human safety studies means we simply don’t know. This isn’t fear mongering. It’s acknowledging uncertainty and uncertainty exists and understanding that if you’re choosing to use peptides like BPC 157, you are doing it in an experimental model. Dr. Deb Muth 22:17We’re experimenting with the doses that are being used. And there is potential for it to cause cancer cells in your body to grow. And you need to be aware of this and understand the risks that you’re taking when you’re using an investigational or off label use peptide. Now, quality control issues with BPC also exist. It’s not FDA approved for any indication in the US. It’s not approved in any major regulatory jurisdiction worldwide. It’s marketed as a research chemical explicitly to bypass FDA oversight. And commercial sources selling BPC-157 range from compounding pharmacies, which have some quality standards but are not FDA inspected. You can take that for what you want to believe on that one. to overseas suppliers operating with absolutely no quality assurance whatsoever. If you are choosing to use BPC-157, you have to understand who’s manufacturing it for you, where you are getting it from, how pure it is. Dr. Deb Muth 23:26You want to make sure that you have the certificate of analysis and that it does not contain bacterial endotoxins that can contaminate the peptide or degrade the peptide and cause other issues for you. So when you talk about peptides with patients regarding BPC-157 or if you’re listening to this and you’re already using BPC-157 or other peptides, that are quote-unquote not for human consumption, an evidence-based response acknowledges both the appeal and the limitations. And you want to talk about the animal data that’s definitely showing some progress and some potential, but we don’t know what we don’t know in humans. If people are willing to take that risk, that is up to them to do that. But using BPC right now is experimental and people need to be aware of that. Are there evidence-based alternatives for patients with tendon or ligament injuries? Dr. Deb Muth 24:26And there are. There’s PRP, which has been studied in multiple randomized controlled trials. for conditions like lateral epicondylitis, tennis elbow, Achilles issues, patellar issues, knee issues. However, I want to caution you on this too. So the study that was done by Cox and colleagues in muscles, ligaments, and tendons in the Journal of 2014 showed modest benefits in pain and function compared to controls. And though the effects vary by injury type, PRP preparations can be helpful. You have to understand that a lot of times when people are doing PRP injections in their office, they are not doing it exactly the same way it was done in the study. And not to mention, if you’re using your own PRP to heal a ligament or a tendon or help your arthritis and you’re 60 or 70 years old, That is not good quality protein rich plasma. It is old protein rich plasma. And you’re not going to see necessarily the same benefits that you would see if you were using placental tissue or umbilical tissue. Dr. Deb Muth 25:33You also want to address the nutritional deficiencies or support that’s needed for connective tissue healing. And these are collagen peptides dosed at 15 grams a day. And this has been shown in a study by Shaw and colleagues in the American Journal of Clinical Nutrition in 2017 to augment collagen synthesis when combined with intermittent loading. Vitamin C is also an essential cofactor for collagen production and stabilization of collagen structure at a dose of around 500 to 1000 milligrams a day to support this process. You also need to have good adequate intake of copper and zinc. These are cofactors in collagen. Silica is also important. This comes from horsetail extract. This provides additional support as well. So more importantly, I think remembering that rehabilitation matters as well. Doing these protocols without doing some rehab is not going to get you where you want to go. Dr. Deb Muth 26:33There’s a research study by Alfredson and others for Achilles tendinopathy using the control lengthening of muscle tendon units under load to promote tendon remodeling and healing. These protocols have solid evidence and cost nothing beyond professional guidance from a physical therapist. They are important for patients seeking cutting edge regenerative approaches. Stem cell therapies, growth factors, concentrates derived from patients’ own tissues like PRP. These have a lot of good endogenous materials and they have good safety profiles. BPC-157 represents the perfect example of how promising Preclinical science gets marketed far beyond the evidence and it may eventually prove to be valuable. I think it will. But right now that determination does require some human studies and hopefully with the administration that we have right now and Bobby Kennedy, we will actually start to see some of that occur. Now the next peptide I want to talk about is TB4, thymus and beta-4. Dr. Deb Muth 27:36This is a wound healing peptide. It is a 43 amino acid peptide that’s naturally present in virtually all human cells except red blood cells. It’s actually one of the most abundant peptides in the human body, particularly concentrated in blood platelets, wound fluid, and many tissues. It’s naturally ubiquity makes it mechanistically interesting. The body wouldn’t produce it in such abundance if it didn’t serve a function. So the primary role of TB4 involves building G-actin. It’s a form of monomeric actin. And it’s structural protein that forms the microfilaments within the cells, providing cellular structure and enabling cell movement. TB4 prevents from F-actin filaments. I’m not going to talk too much about this. It’s really critical for wound healing as cells need to migrate into the injury sites. Dr. Deb Muth 28:37so the cell shape changes and the cellular response to the injury. So think of this as though you tore your meniscus and the body created all this TB4 to come to that injury to try to heal that site. That’s exactly what the TB4 is doing inside the body when there’s an injury. It’s been shown in research to help produce new blood vessel formation, promote endothelial cells, It helps modulate inflammatory cytokines, potentially reducing TNF-alpha, IL-1, and possibly protecting in programmed cell death, which we call apoptosis. And some studies suggest that it is cardioprotective in its effects in animal models of myocardial infarction, so heart attack, and neuroprotective in other models for brain injury. Now, these remain to be preliminary, but they are being seen. So the regulatory status on TB4 can create some confusion. Dr. Deb Muth 29:40The natural TB4 molecule itself is not FDA approved as a drug. However, TB4 based drug candidates called RGN259, formerly TB4, has been in the development by regen tree for corneal injuries of the dry eye disease. And as of recent updates, this drug is completed phase three trials for its neurotrophic keratopathy, severe corneal condition. But the FDA approval is still pending. So that means that the most advanced TB4-based pharmaceuticals hasn’t yet crossed the finish line for approval. The commercial peptide market further muddies the picture with TB500, which is often described as the synthetic fragment of TB4. However, this extract’s relationship between TB500 and TB4 varies depending on the source. Dr. Deb Muth 30:41So some claim that TB500 is identical to TB4, but positions 1 through 4 suggest it’s a different fragment. and the quality control across suppliers is not existent. So this confusion is part of why recommending TB500 becomes problematic for practitioners and patients, often because they aren’t certain what molecule they’re actually getting. The evidence base for TB4 in humans is limited, primarily to eye research, and the studies from Sohn’s and colleagues published in journals like Vitamins and Hormones in 2016 have examined topical TB4 for corneal injuries and neurotrophic keratopathy, dry eye, and other surface diseases. Now, these studies showed some promise in promoting this, and there is, however, a topical application to the cornea that is vastly different from a systemic injection. So for systemic use in wound healing, musculoskeletal issues, Dr. Deb Muth 31:42cardiac protection, neuroprotection, human clinical trials. There is scarce to non-existent evidence in humans. Most of the evidence remains in animal models or cell culture studies. And a review by Flip and colleagues in the Journal of Investigational Dermatology in 2006 detailed TB4’s effects on the matrix remodeling during wound repair in animal models, showing effects on collagen disposition, granulation, tissue reformation, and wound contraction. Another review by Ho and colleagues in expert opinion on biological therapy in 2007 discussed TB4’s potential in tissue regeneration and regenerative medicine, but noted the field remained largely blank. preclinical. So this is really important again to understand that there is just not enough human data. So there is a concern with cell division and migration. This theoretically exists Dr. Deb Muth 32:45for the potential effects on cancer cells, which would also rely on migration and division and other intended consequences of disrupting normal cellular architecture. These aren’t proven risks, but they are unexplored questions that we need to be aware of when we’re using peptides. This can cause cancerous tissue to grow. Very similar to what we talked about with BPC-157. These are also sold as research chemicals. There is no FDA oversight. So purity, potency, contaminations all still exist for these peptides. Now from an integrative perspective, the natural presence of TB4 in wound fluid and its biological roles in healing are legitimate science. in presence does not equal therapeutic utility. The body tightly regulates where and when and how much TB4 is present through natural production and bypassing that regulation with external dosing may or may not cause us to have beneficial or introduce risk. Dr. Deb Muth 33:49So we need to know that this is experimental use. Those people who are seeking wound healing and tissue repair the evidence-based approach of the body’s own capacity to heal is huge definitely want to be increasing your protein intake optimizing your zinc copper vitamin c and vitamin a and then managing glucose is really important during this time as well so let’s talk about a fun topic now and that’s growth hormone secretagogues this is the anti-aging hype machine these peptides in this category are things like semoralin ipameralin cjc 1220 1295 and others and among the most aggressively marketed in anti-aging and longevity medicine they all share a common goal stimulating the pituitary gland to release more growth hormone and the appeal is understandable. GH levels decline with age, and this decline is associated with increased fat mass, decreased lean muscle, reduced bone density, and other aspects of aging. Dr. Deb Muth 34:55The other times we’ll see growth hormone levels decline significantly is with chronic illness, and the logic is to restore youthful GH levels and youthful physiology. Now, semirelin from an FDA approved diagnostic to compound anti-aging product. Semirelin is a 29 amino acid peptide representing the first 29 amino acids of the full 44 amino acid human growth releasing hormone, GHRH. We talked about this on another episode of the podcast. And you can go back and listen to that one a little bit if you want. This fragment contains the complete biological activity of the full GHRH molecule and it binds to GHRH receptors in the anterior pituitary and stimulates growth releasing peptides, growth hormone releasing peptides. Semirelin was previously FDA approved as diagnostic testing of growth hormone secretion, essentially, to determine if the pituitary could still respond to GHRH stimulation in patients being evaluated for growth hormone deficiency. Dr. Deb Muth 36:06However, the manufacturer was discontinued and there was no longer an FDA approved semirelin product on the market in the United States. What exists now is semirelin available from compounding pharmacies used off label for anti-aging, body composition, and general growth hormone optimization purposes. This represents a significant gray area. Again, compounding medications serve a very important role, but they need to meet certain recommendations and regulations, as we’ve talked about in the past. You want to make sure that your compounding pharmacy that you’re obtaining semirelin from is qualified to do that, that they are doing best practices, and that you’re getting a good product. The theoretical advantage to semirelin over direct growth hormone administration is that it preserves more of the physiological growth hormone secretion patterns. Natural GH is released in pulses, primarily during sleep, not as a continuous elevation. Dr. Deb Muth 37:07So semirelin stimulates the pulses rather than providing a constant super physiological growth hormone level. And that pulsatile pattern is thought to reduce some of the side effects and metabolic concerns that we have with continuous growth hormone exposure. However, the evidence supporting semirelin for anti-aging and body composition in healthy adults is minimal. Most of the data comes from studies conducted in the 1990s when the FDA approved product existed. Not that that means it’s bad. We have drugs that have been in the market for over a hundred years that are still there, that still have the research and are still being used successfully and safely today. So we don’t want to let that really make us think that this product isn’t safe. So a 2006 review from Walker in Clinical Interventions of Aging suggested that semirelin might be a better approach than direct GH for adult onset growth hormone insufficiency, but they do acknowledge that the evidence was limited. Dr. Deb Muth 38:12And although we don’t have any large scale trials that we can examine for semirelin’s efficacy, it is now commonly prescribed. And the optimal dosing for anti-aging purposes is still unknown. It is considered experimental and it does vary from person to person, but it is still unstudied. The effects on cancer risk, cardiovascular disease, metabolic dysfunction over long time periods are also still unknown. I would argue that the side effects or the risk factors of not having growth hormone are equally as bad as the unknowns that we have here. We’re not looking to try to get super physiological doses. We’re trying to restore youthful GH levels. Typically, we’re not trying to restore back to a 20-year-old. We’re trying to restore back maybe 10 years. That is a better way of doing this. And I think that’s important for people to understand. Now, ipamirelin is the ghrelin mimicker. Dr. Deb Muth 39:12Ipamirelin is a pent-up peptide, five amino acid, that acts as a growth hormone secretagogue receptor, a GHS-R agonist. It mimics the action of ghrelin, the hunger hormone, that also stimulates growth hormone release. The proposed advantage over earlier secretagogues is that ipamirelin stimulates growth hormone release without significantly affecting cortisol, prolactin, or other glucose things, which can be increased by growth hormone secretagogues. The regulatory status is clear. Ipamirelin is not FDA approved for any indication. It’s sold as a research chemical. Human evidence is thin. It’s limited to single dose studies examining how quickly it’s absorbed and metabolized with minimal data on dosing and clinical outcomes. Now there are marketing claims for ipamirelin and they are extensive. Dr. Deb Muth 40:13It increases lean muscle mass, it decreases body fat, it improves sleep quality, faster recovery from workouts, enhanced injury healing, better skin quality. The evidence supporting these claims in humans is not available we don’t have it these are claims that are made by the effects that we know from growth hormone so it’s not necessarily a bad thing we know what growth hormone does we know growth hormone does all of these things if ipamorelin is a precursor to that it will obviously help improve those things making that correlation of what growth hormone does So there are safety concerns that mirror the same as any other growth hormone elevating therapy. It can cause fluid retention, joint pain, carpal tunnel syndrome, insulin resistance, glucose intolerance, and theoretically, can it increase calcium? cancer risks? It can because IGF-1 promotes cell proliferation and can inhibit apoptosis in cancer cells. Now remember, your body makes IGF-1. Dr. Deb Muth 41:15If it’s not making enough of it, that’s a problem. If it’s making too much of it, That’s a problem. So just understand that if you are adding these things, and especially in elevated doses, you are taking a potential risk. So there is also now CJC 1295 is a modified GHRH analog of 30 amino acid peptide based on GHRH structure, but with modifications. So it includes the addition of drug affinity complex, DACC, DAC, which involves conjugation with a small albumin binding molecule, dramatically extends the peptide’s half-life from minutes to as much as potentially a week or more. And this creates sustained growth hormone elevation rather than that pulsatile release. There are actually two versions of this. There’s CJC 1295 with DAC, longer acting version, and CJC 1295 without DAC, which is essentially a shorter duration of semirelin. Dr. Deb Muth 42:19And so when we’re comparing products, it is… only the difference between long acting and short acting. The human evidence for CJC 1295 is limited to a single published phase one study by Techman and colleagues in the Journal of Clinical Nutrition and Metabolism in 2006. And the study involves 18 healthy young adults showed that CJC 1295 with DAC produced a sustained elevation of GH and IGF-1 lasting several days after the injection. That’s essentially the entire published human evidence of this peptide. There are no phase two studies examining optimal dose. So that is all considered experimental. And there is no phase three studies examining clinical efficacy. So the sustained GH levels created by CJC 1295 with DAC raises specific concerns because the natural GH secretion It goes up and down, up and down, up and down. Dr. Deb Muth 43:19And that constant elevation may have a different metabolic and cellular effect. And we just really don’t know what that’s going to be yet. So we can understand that elevated IGF-1 levels can theoretically increase cancer concerns and metabolic risks. So rather than always injecting peptides, which are very expensive… You can do other things. And there was a study by Hartman and colleagues in the Journal of Clinical Endocrinology and Metabolism in 1992 that demonstrated the 48-hour fast increased integrated growth hormone secretion five-fold through increased GH levels. Now, the problem with this is fasting for 48 hours is a challenge. And how long is it going to increase the growth hormone secretion without causing issues? Or in general, how long is it going to go up? Dr. Deb Muth 44:19So we have to be cautious about that as well. Sleep optimization is non-negotiable. The majority of growth hormone secretion occurs during sleep, slow wave sleep, typically the first sleep cycle, and poor sleep quality or insufficient sleep typically. can dramatically affect your growth hormone levels. And then high intensity interval training, HIIT resistance training can stimulate growth hormone as well. This was seen in a study by Godfrey and colleagues in sports medicine in 2003 and was examined in exercise-induced growth hormone responses to athletes. So we definitely see these kinds of things. So let’s talk about some longevity peptides now. These expand the telomere. So there’s epitalin and epithalamin and when these are used in anti-aging they can produce some amazing results. Dr. Deb Muth 45:22So epitalin is a synthetic terapeptide, just four amino acids. It was originally synthesized as a simplified version of epithalamine. a pineal gland extract containing multiple peptides. The synthetic four amino acid version was created to isolate what researchers believed might be the active anti-aging component. The mechanism produced for epitalin centers on telomere and telomerase, Telomeres are protective caps at the end of the chromosomes consisting of repetitive DNA sequencing. And every time a cell divides, telomeres shorten slightly because DNA polymers cannot fully replicate the ends of the linear chromosomes. So this progressive shortening acts as a molecular clock. After 50 or 70 divisions, the telomeres become critically short, triggering a cellular senescence. Dr. Deb Muth 46:22This telomere shortening is one mechanism of cellular aging and telomeres in the enzyme that can rebuild telomeres by adding these caps back onto the end of the chromosome. It’s active in stem cells, germ cells, and unfortunately in about 85 to 90% of the cancer cells. In most adult somatic cells, telomerase is inactive or present at very low levels, allowing the telomeres to shorten with division. The research on epitalin suggests it might activate this telomeres act telomeres process primarily from a research group led by Vladimir in Russia. Vladimir Kavasan in Russia. He is a huge peptide researcher or was he passed away with publications dating back to the early 2000s and a study published in bio gerontology in 2000 by Kavasan Dr. Deb Muth 47:25and colleagues examined the effect of epitalin on the lifespan of fruit flies, and they treated fruit flies that showed a modest increase in mean and maximum lifespan compared to its controls by approximately 10 to 15% lifespan extension in some experimental groups. And there were other studies in 2003 that examined epitalamine in a female Swiss-derived mouse. This was done by Ann Simove and colleagues. And the researchers reported that epitalin treatment was associated with increased lifespan as well. And the most cited mechanistic work comes from cell culture studies. And that is also Cavason’s group that published this research in 2003, showing increased telomeres activity in cultured somatic cells again. More recently, between 20 and 25, the series of publications have continued to explore epithelial effects on telomere dynamics in cell cultures. Dr. Deb Muth 48:32So there is a lot of research that’s been done. The mass majority has been done on epithelin. And most of it has been done by a single research group in Russia. There is some restrictions on some of the cell culture data that we’re seeing. And it does show that epithelin sometimes can be described as a regulating hormone. Carcadian rhythm for melatonin production, which is derived by the penile extracts. And however the evidence for this affects minimally and mechanistically unclear, the pineal gland primarily functions as melatonin secretion in that light-dark cycles. So Epithalin or epitalin is not FDA approved. It is not approved for any major regulatory jurisdiction. It is sold as a research chemical only. Dr. Deb Muth 49:33So you need to follow the same safety profiles that we’ve talked about in other episodes and in today’s episodes. And when we’re talking about epithalin, and we’re excited about it being an anti-aging science, we should balance this with the honesty and the evidence of the quality of that evidence. We don’t know its safety effect. We don’t know if it’s going to increase the risk of cancer. We can’t verify that. And we need to be using it in an experimental use of unknown risks only. Of course, diet, physical activity, stress management, sleep quality, all of those things are important for us to be looking at when we’re looking at these peptides. Now, I want to get into some of the brain peptides. This is the nootrophic frontier. C-Max and C-Lank, there is Russian pharmacology that’s done. C-Max and C-Lank represent an interesting case study in how different regulatory environments and research traditions Dr. Deb Muth 50:36create challenges in evaluating this evidence. Both peptides were developed in Russia, are approved for their specific indications and have substantial Russian language and literature supporting their use. However, the FDA approval in the United States is still not there. C-Max is a seven amino acid. It’s a synthetic analog. It is a fragment, particularly ACTH 4 through 10. It’s sometimes called the melanocortin effects because it involves the melanocortin receptors of the central nervous system. CMAX was developed by the Institute of Molecular Genetics of Russia Academy of Sciences and is approved in Russia for several indications, including acute stroke, transient ischemic attacks, cognitive disorders. It has Russian approval and is based on clinical trials primarily in Russia. Dr. Deb Muth 51:39It does help to increase brain-derived neurotrophic factor, BDNF, a protein critical for neuroplasticity, the brain’s ability to form new connections and adapt to the challenges. BDNF supports neuronal survival and promotes growth of these new neurons. C-Max also influences neurotransmitter systems, particularly dopamine and serotonin, and there is some research that suggests it affects on metabolism as well, and endogenous opioid peptides that involve pain reception and mood regulation. So it has some good potentials there. There is also C-Link, which is a hepatopeptide structurally similar to Tufts’ and an immune modulatory peptide. It was also developed in Russia and was approved for anxiety disorders as a neurotropic. Its effects involve anxiolytic effects, possibly through the GABAnergic system or the GABA system of the brain, and immune modulation. Dr. Deb Muth 52:44The Russian research is examined by C-Link for anxiety disorders. and finding reductions in anxiety without sedation. There is a dependency potential or cognitive impairment does not exist like it does with benzodiazepines with C-Link. So that is really good. And they do report attention and memory improvement using C-Link. There is a study that was done in neuroscience and behavioral psychology in 2018 that examined C-Linx effects and proposed that it exerts cytoprotective effects through BDNF pathways similar to C-Max. So both of these are Russian research-based They’re not wrong or fraudulent. It’s just that they are from Russia and we all have our concerns with Russia. However, that does not necessarily mean their research doesn’t hold quality. Dr. Deb Muth 53:49Neither peptide is approved by the FDA, and so you are using this off-label. The same rules apply for all of the other peptides that we’ve talked about that are produced off label. You want to do the same things that you would do with anything else. Good protein, omegas, B vitamins, acetylcarnitine, exercise, sleep, all of that still applies when we’re using these peptides. So I want to talk briefly about clinical decision and framework when we’re looking at this. First and foremost, we always want to go to FDA-approved peptides. Secondly, we would look at international approval with peptides that are established in other countries but lack FDA approval. And then preclinical evidence only or experimental peptides. These can be used, but they are not ethically recommended in the traditional medicine world. Dr. Deb Muth 54:50 If patients use them, we need to have appropriate counseling about the evidence surrounding them, the safety, and where to find them. how to find them and how to ask for these certificates of analysis. So I think it’s really good that we were exploring all these peptides and understanding what they are. There’s a lot of controversy out there. There’s a lot of concern out there. And what we can say with confidence is that peptides are powerful biological signaling molecules. Some peptide based medications, semi-glutide, triseptide, PT 141, Lupron that are all FDA approved. can dramatically improve outcomes in patients that are obviously selected for the correct ones. There are many other peptides that we address that are integrative and longevity space in the regenerative medicine. These peptides are all experimental. That does not automatically make them wrong. Dr. Deb Muth 55:50It just means that we need to be honest about what we’re doing with them and we need to be cautious with the patients so that they can make a decision to be part of an experimental study. in looking at how to use these peptides. So peptides are tools like any other tools. They work best in the hands of skilled people, and they are applied to appropriate situations, integrating into comprehensive approaches that address root causes. The most powerful peptide administered to a patient with untreated inflammation, hormonal chaos, nutritional deficiencies, and disorders of sleep will disappoint. The simplest evidence-based interventions apply. to a patient whose foundational physiology has been optimized. And this is the art of the science of peptide, right? If done right, respecting both the power of these molecules and the complexity of human beings that we are privileged to serve can make a difference in their lives. So thank you for listening to this episode. Dr. Deb Muth 56:52I hope this was helpful. If you can know of somebody that might benefit from this, please like, share, and subscribe. It means a lot to us. And I hope you join us for our next episode of Let’s Talk Wellness Now. Welcome to Let’s Talk Wellness Now, where we bring expert insights directly to you. Please note that the views and information shared by our guests are their own and do not necessarily reflect those of Let’s Talk Wellness Now, its management, or our partners. Each affiliate, sponsor, and partner is an independent entity with its own perspectives. Today’s content is provided for informational and educational purposes only and should not be considered specific advice, whether financial, medical, or legal. While we strive to present accurate and useful information, we cannot guarantee its completeness or relevance to your unique circumstances. We encourage you to consult with a qualified professional to address your individual needs. Dr. Deb Muth 57:54Your use of information from this broadcast is entirely at your own risk. By continuing to listen, you agree to indemnify and hold Let’s Talk Wellness Now and its associates harmless from any claims or damages arising from the use of this content. We may update this disclaimer at any time and changes will take effect immediately upon posting or broadcast. Thank you for tuning in. We hope you find this episode both insightful and thought-provoking. Listener discretion is advised.The post Episode 258 – Investigational Peptides: What's Promising, What's Hype & What You Must Know first appeared on Let's Talk Wellness Now.

This was a delectable Sunday crossword by Jill Rataloff and Michelle Sontarp, who happen to both work at the same law firm. That might explain 21A, Certain head jurors, FOREMEN, and 125A, Bars, legally, ESTOPS, but does not explain the remainder of this fine puzzle. That's what we, amici curiae, are here to do (as well as show off our knowledge of Latin, or at least how to use Google Translate

Ephesians 3:14-21A community transformed by grace sent to transform the world for the glory of God.WEBSITE: https://c3lr.orgFACEBOOK: facebook.com/C3.LittleRockINSTAGRAM: instagram.com/c3.littlerockSERMON PODCAST:  https://c3littlerock.buzzsprout.com

Verse by Verse – Parables, Week 12Pastor Nathan Zickert · Luke 12:16–21A video recording of this sermon is available here.For more information about Grace Community Church of Riverside, visit us online at https://www.gccriverside.com.

OPEN HEAVENSMATALA LE LAGI MO LE ASO TOONAI 4 OKETOPA 2025(tusia e Pastor EA Adeboye) Manatu Autu:   Vavega fou (New miracles) Tauloto Tusi Paia –  Galuega 9:12 “o lea ‘ua ‘avea ai solosolo po o ‘ie tali ‘ele‘ele nai lona tino i ē mama‘i, ‘ona mavae ai lea o latou ma‘i, ‘ua ō i fafo fo‘i ‘iā te i latou agaga leaga.”‭‭Faitauga - Tusi Paia: Isaia 43:18-21A finagalo le Atua e tapena le tulaga mo ni mea fou, e masani ona Ia amata e ala i le faia o vavega ma faamanuiaga fou. Ina ua finagalo le Atua e fa'asa'oloto le fanauga Isaraelu mai le nofo pologa I Aikupito, na amata I le fa'aaoga o le to'oto'o o Mose e faatino ai le tele o vavega e le'i vaai muamua I ai se isi (Esoto 4:17). Ina ua afio mai Iesu e faia se feagaiga fou, na Ia faia ni vavega fou se tele, na fai mai tagata e le'i vaai muamua lava o tupu se mea faapea talu mai anamua (Mareko 2:12). E Faapena fo'i Ina ua o'o I le taimi e o ai le au aposetolo e tāla'i le Talalelei i tala atu o Ierusalema i Samaria, Iutaia ma itu uma o le lalolagi, na amata malolo tagata mama'i i le ata lafoia o Peteru (Galuega 5:15). Ia te a'u lava ia, ua ou maitauina soose taimi e finagalo ai le Atua e siitia i matou i se tulaga fou i le RCCG, e muamua lava Ia faia ni vavega fou matou te lei vaai muamua i ai.I tausaga ua mavae sa fai ai se tauaofiaga a le mafutaga a tamaloloa fai pisinisi faavaomalo a le Full Gospel i Port Harcourt, o se taulaga i Nigeria i Saute ma sa valaaulia ai a'u oute talanoa i le mataupu o le “faauuga fou”. Sa o'u faamatala ni fa'ata'ita'iga o mea na faia e le Atua i lona alofa mutimutivale le faatuaoia e ala ia te a'u. Ina ua o'o i le taimi e o ai i aiga, na amata gaioi mai agai i luma le faapotopotoga ma sa manaomia ai ona puipui ma taitai a'u i la'u taavale. O se fafine sa iai, e iai sona uso, e matua'i faaletonu le mafaufau, sa naunau a lē mafai ona pai mai ia te a'u o lea alu e pa'i i la'u taavale. O lea na ia aumaia ai se solosolo tuu i luga o le taavale na o'u iai i totonu ma ia toe aveese a'o lei alu ese le taavale. Ina ua taunuu i lona aiga, sa ia fai i ni tagata malolosi se toaono e taofiofi lona uso. Na ia talotalo le solosolo ma faapea, “ua i lo'u lima le tali o le fa'afitauli”. Ona ia ave lea o le solosolo ma tu'u i luga o lona uso ona toe fo'i lea o ia i ona uiga masani ua malolo. A finagalo le Atua e siitia oe i se isi laasaga fou e masani lava ona amata i vavega fou. O lea, e tatau ai lava ona e vaavaai ma maitau ni ituaiga vavega faapea i lou olaga ia mafai ai ona e malamalama i ou vaitau. E ese mai lou vaavaai mo vavega faapea, e mafai fo'i ona e ole i le Atua e foa'i mai. I le Galuega e 4: 29-30, na ole le au aposetolo i le Atua ia faatasi ma i latou i le talaiina o le talalelei, i le faaloaloa mai o lona ‘a'ao e faamalolo ai e mama'i ma faia faailoga ma vavega. O le tali o lea tatalo, na mata'utia le tupu ma ola o le ekalesia (Galuega 4:31-33). Le au pelē, ole atu i le Atua mo ni vavega fou i lou olaga i le asō. O lou faia fa'apea o le a e amatalia ai se tautotogo i se vaitau fou o lou olaga. Ole atu i le Atua e amata se mea fou i lou olaga i le asō i le foai atu lea o ni vavega fou, i le suafa o Iesu, Amene.

É a história de uma noite na vida de Paul Hackett (Griffin Dunne), um operador de computador que trabalha no centro de Manhattan e odeia seu trabalho, como também não suporta sua solitária vida particular. Na noite em questão, cansado de ficar sozinho em casa, foi ler em um restaurante. Lá uma bela e encantadora jovem, que estava em outra mesa, puxa conversa dizendo que adora o livro que ele está lendo. Logo está na mesa dele e os dois conversam animadamente, parecendo compartilhar de alguns interesses comuns. Ela lhe diz que está indo para a casa de uma amiga, que é escultora e mora no Soho. Ela diz que sua amiga faz um tipo de trabalho que ela vende como peso para papel e pergunta se Paul quer comprar. Ele não tem o menor interesse, mas a mulher que está à sua frente lhe desperta muitas coisas, e assim diz que quer comprar. Como ela não sabe o preço dá o telefone de Kiki Bridges (Linda Fiorentino), a escultora, e vai embora. Já em casa, Paul liga para Kiki, usando como pretexto seu interesse por pesos para papel. Logo Kiki lhe diz que a jovem com quem falou chama-se Marcy, que vai ao telefone e sugere que ele a encontre no apartamento do Soho. Ele concorda prontamente, mas o que poderia ser uma noite agradável torna-se o início de uma noite conturbada. Os problemas já começam no caminho, quando Paul deixa voar pela janela do táxi sua única nota de vinte dólares. As ruas de Soho estão escuras e abandonadas, como um mau presságio. Marcy está passando alguns dias no apartamento de Kiki, que faz esculturas estranhas, tem gostos sexuais "excêntricos" e conversa estranhamente, ocultado ter sido queimada. No quarto de Marcy, Paul tem a conversa sucinta de um primeiro encontro e ela diz que seguramente eles terão grandes momentos. Entretanto tudo começa a dar e uma sucessão de eventos infernam a vida de Paul. Esta maré de má sorte vai em um crescendo, ao ponto de ser perseguido por uma turma que crê que Paul seja um bandido.PIX: canalfilmesegames@gmail.comSiga o Filmes e Games:Instagram: filmesegames Facebook: filmesegames Twitter: filmesegamesSpotify: https://open.spotify.com/show/5KfJKthPodcast: https://anchor.fm/fgcastIntro - 0:00Afta Aurs - 3:37O que é "Depois de Horas" - 4:55Notas dos agregadores - 9:40Tirando o bode da sala - 10:21A história de Depois de Horas - 31:05Curiosidades e análise - 39:27Bilheteria - 59:19Notas do Filmes e Games - 59:41Momento Locadora - 1:03:14Revelação do FGcast #396 - 1:42:45Dicas do FGcast #396 - 1:50:45

Supreme , Week 9 Pastor Nathan Zickert · Colossians 3:18-21A video recording of this sermon is available here.For more information about Grace Community Church of Riverside, visit us online at https://www.gccriverside.com.

Sunday Morning, July 20, 2025How are we to live? - When You Encounter Evil ... Romans 12:17-21A message delivered by Richard Fleming

W Biblii tego apostoła określa dwoma imionami, ale ponieważ używano wtedy kilku języków można powiedzieć, że miał pięć różnych określeń. Aż trzy pojawiają się w Jana 1:42, gdzie czytamy: “Jezus, spojrzawszy na niego, rzekł: Ty jesteś Szymon, syn Jana; ty będziesz nazwany Kefas (to znaczy: Piotr)”. Mamy tutaj imiona Szymon i Piotr są w języku greckim, a Kefas prawdopodobnie w aramejskim. W Dziejach Apostolskich Jakub nazywa go Symeonem (Dzieje 15:14), a Mateusz w swojej Ewangelii Szymonem Piotrem. Hebrajskie imię Symeon znaczy “słuchać”, a imię Piotr i Kefas można przetłumaczyć jako “Skałosz”.Ewangelista Jan opisuje pierwsze spotkanie Piotra z Jezusem niedługo po chrzcie tego ostatniego. W Jana 1:44 czytamy: “Filip był z Betsaidy, miasta Andrzeja i Piotra”. Później musiał się jednak przeprowadzić z Betsaidy do Kafarnaum. W Łukasza 4:38 czytamy: “wyszedłszy z synagogi, wstąpił do domu Szymona. A teściowa Szymona miała wielką gorączkę”. Jezus był w synagodze w Kafarnaum i stamtąd od razu poszedł do domu Piotra. Czyżby Piotr nie tylko się przeprowadził, ale także ożenił w międzyczasie? Napiszcie mi co o tym myślicie? Oba miasta Betsaida i Kafarnaum znajdują się na północy Jeziora Galilejskiego, a więc stosunkowo blisko siebie.Niektórzy zwracają uwagę, że Ewangelie mówią tylko o teściowej, ale o żonie pisał Paweł w 1 Liście do Koryntian 9:5, gdzie czytamy: “Czy nie wolno nam zabierać z sobą żony chrześcijanki, jak czynią pozostali apostołowie i bracia Pańscy, i Kefas?” Wynika z tego, że Kefas czyli Piotr w swoje podróże zabierał ze sobą swoją żonę. Biblia niewiele miejsca poświęca kobietom, ale np. w Marka 15:41 czytamy o niewiastach: “Które, gdy był w Galilei, chodziły za nim i posługiwały mu, i wiele innych, które wraz z nim przyszły do Jerozolimy”. Z Jezusem chodzili nie tylko apostołowie, ale także kobiety. Być może także żona Piotra, która później z nim podróżowała może aż do Babilonu.Czy Piotr był najważniejszym apostołem? Warto zwrócić uwagę na kilka rzeczy, które go wyróżniały. Tylko jemu Jezus zmienił imię, którym się później posługiwał nie tylko on, ale także inni, np. Łukasz w Dziejach Apostolskich. Piotr wielokrotnie przemawiał w imieniu wszystkich apostołów, np. pytał o wyjaśnienie przykładów mówiąc: “wyjaśnij nam”. Gdy Jezus zadawał pytanie apostołom odpowiadał Piotr, np. w Jana 6:68 czytamy: “Odpowiedział mu Szymon Piotr: Panie! Do kogo pójdziemy? Ty masz słowa żywota wiecznego”. Zwróćmy uwagę, że Piotr mówi w liczbie mnogiej, za wszystkich apostołów.Jednak to, że Piotr pierwszy zabierał głos i wypowiadał się w imieniu całej dwunastki można wytłumaczyć na dwa inne sposoby. Piotr był najprawdopodobniej najstarszym apostołem. W kulturze żydowskiej pozycja była bardzo ważna i wiązała się z zabieraniem głosu oraz miejscem przy stole. Piotr z ewangelii jawi się jako człowiek, który szybciej mówi niż myśli. Wygląda na to, że niektóre z jego wypowiedzi wynikają z tej cechy charakteru. Np. w Marka 9:6 czytamy, że nie wiedział co powiedzieć bo się bał. Mimo to, a może właśnie dlatego, że się bał i nie wiedział co powiedzieć, powiedział to co mu przyszło mu do głowy i nie było to zbyt mądre.Jezus jednak przy kilku okazjach wybierał kilku apostołów do specjalnych zadań. Np. do domu Jaira gdzie leżała jego córka zabrał tylko Piotra, Jakuba i Jana. Tak samo było podczas przemienienia oraz w ogrodzie Getsemani. Podczas rozmowy o znakach dni ostatnich oprócz tej trójki był jeszcze obecny Andrzej brat Piotra. Kiedy później wybierano nowego apostoła na miejsce Judasza w Dziejach 1:21 czytamy o wymaganiach do których zaliczano świadczenie o tym co robił Jezus. Jednak Piotr, Jan i Jakub widzieli więcej niż reszta apostołów. Z tych trzech wydaje się, że Piotr i Jan mieli szczególnie miejsce i to nie tylko obrazowo, ale wręcz dosłownie.Choć Jan miał brata Jakuba, a Piotr Andrzeja wygląda na to, że Jezus wybrał tych dwóch do pewnych specjalnych rzeczy, a oni współpracowali razem nawet po jego śmierci. To Piotr i Jan zostali posłani aby przygotować ostatnią wieczerzę. To oni siedzieli najbliżej Jezusa. To także ci dwaj pobiegli do grobu Jezusa po zmartwychwstaniu. W Jana 20:4 czytamy: “A biegli obaj razem; ale ów drugi uczeń wyprzedził Piotra i pierwszy przyszedł do grobu”. Później w Dziejach Apostolskich 3:1 czytamy: “A Piotr i Jan wstępowali do świątyni w godzinie modlitwy, o dziewiątej”. Działali razem, razem stanęli przed Sanhedrynem. Także Piotr i Jan zostali wysłani przez apostołów do Samarii jak czytamy w Dziejach 8:14.Czy Piotr był najważniejszym apostołem? Wszystko zależy od tego co przez to rozumiemy. Np. gdy wynikła kwestia obrzezania pogan w Dziejach 15:22 czytamy: “Wówczas postanowili apostołowie i starsi razem z całym zborem”. Zauważmy, że decyzji nie podjął sam Piotr, ani nawet sami apostołowie. Jeżeli więc nawet uznamy Piotra za najważniejszego apostoła nie oznacza to, że to on podejmował decyzje wiążące wszystkich. Niestety Piotr pojawia się w Dziejach Apostolskich ostatni raz w tym 15 rozdziale.W Galatów 2:11 dowiadujemy się: “A gdy przyszedł Kefas do Antiochii, przeciwstawiłem mu się otwarcie, bo też okazał się winnym”. Wynika z tego, że Piotr dotarł do Antiochii Syryjskiej i tam był skarcony przez Pawła wobec całego tamtego zboru. Z 1 Listu Piotra 5:13 wynika, że był z żoną i Markiem w Babilonie. Tradycja podaje, że jego żona miała na imię Perpetua. Marka nazywa tam synem, ale prawdopodobnie chodzi o Ewangelistę Marka, który był jak syn dla tego apostoła. Czy jednak apostoł Piotr był w Rzymie i tam zginął?Choć wcześniejsze źródła, takie jak List Klemensa Rzymskiego (koniec I wieku) i Ignacego Antiocheńskiego (początek II wieku), już sugerują obecność Piotra w Rzymie, to Ireneusz z Lyonu (koniec II wieku) jest jednym z pierwszych autorów, który wprost i szczegółowo wspomina o założeniu Kościoła w Rzymie przez Piotra i Pawła. W pierwszym wersecie 1 Listu Piotra czytamy: “do wychodźców rozproszonych po Poncie, Galacji, Kappadocji, Azji i Bityni”. Piotr pisze z Babilonu list do chrześcijan na terenie dzisiejszej Turcji. Był to teren Pawła, o czym ten wspomina w Liście do Galatów. Zresztą sam Piotr w drugim liście mówi o listach Pawła skierowanych do zborów na tym terenie. Czy Piotr przybył na teren dzisiejszej Turcji osobiście i czy poszedł dalej do Rzymu?Niektórzy wzmiankę o Babilonie z Listu Piotra interpretują jako określenie Rzymu. Jednak w tamtym momencie dużo Żydów mieszkało w prawdziwym Babilonie, a jak napisał Paweł w Liście do Galatów on miał iść do pogan, a Piotr do Żydów. Gdy my dzisiaj coś określimy jako Babilon to nie ma wątpliwości, że używamy porównania, że mówimy o jakimś innym mieście, bo ten prawdziwy to ruiny. Ale w tamtych czasach było to jedno z wielu zamieszkanych miast, w którym była duża populacja Żydów.Napiszcie mi w komentarzach co wy myślicie na temat apostoła Piotra. Czy według was był on najważniejszym apostołem? Czy był on w Rzymie oraz czy tam zginął jak mówi późniejsza tradycja? Na dzisiaj to już wszystko. To był taki odcinek oparty głównie na historii opisanej w Biblii. Chciałbym jeszcze kiedyś nagrać taki odcinek oparty bardziej na przypuszczeniach i skupić się na tym co Piotr robił przed spotkanie Jezusa oraz co robił później, kiedy Biblia już o nim milczy. Napiszcie mi też czy chcielibyście posłuchać takiego gdybania.I przyprowadził go do Jezusa. Jezus, spojrzawszy na niego, rzekł: Ty jesteś Szymon, syn Jana; ty będziesz nazwany Kefas (to znaczy: Piotr).http://biblia-online.pl/Biblia/Warszawska/Ewangelia-Jana/1/42Szymon opowiedział, jak to Bóg pierwszy zatroszczył się o to, aby spomiędzy pogan wybrać lud dla imienia swego.https://biblia-online.pl/Biblia/Warszawska/Dzieje-Apostolskie/15/14A odpowiadając Szymon Piotr rzekł: Tyś jest Chrystus, Syn Boga żywego.https://biblia-online.pl/Biblia/Warszawska/Ewangelia-Mateusza/16/16A Filip był z Betsaidy, miasta Andrzeja i Piotra.https://biblia-online.pl/Biblia/Warszawska/Ewangelia-Jana/1/44A wyszedłszy z synagogi, wstąpił do domu Szymona. A teściowa Szymona miała wielką gorączkę i wstawiali się u niego za nią.https://biblia-online.pl/Biblia/Warszawska/Ewangelia-Lukasza/4/38Czy nie wolno nam zabierać z sobą żony chrześcijanki, jak czynią pozostali apostołowie i bracia Pańscy, i Kefas?https://biblia-online.pl/Biblia/Warszawska/1-List-do-Koryntian/9/5Które, gdy był w Galilei, chodziły za nim i posługiwały mu, i wiele innych, które wraz z nim przyszły do Jerozolimy.https://biblia-online.pl/Biblia/Warszawska/Ewangelia-Marka/15/41Odpowiedział mu Szymon Piotr: Panie! Do kogo pójdziemy? Ty masz słowa żywota wiecznego.https://biblia-online.pl/Biblia/Warszawska/Ewangelia-Jana/6/68Nie wiedział bowiem, co ma powiedzieć, bo ogarnął ich lęk.https://biblia-online.pl/Biblia/Warszawska/Ewangelia-Marka/9/6Trzeba więc, aby jeden z tych mężów, którzy chodzili z nami przez cały czas, kiedy Pan Jezus przebywał między namihttps://biblia-online.pl/Biblia/Warszawska/Dzieje-Apostolskie/1/21A biegli obaj razem; ale ów drugi uczeń wyprzedził Piotra i pierwszy przyszedł do grobuhttps://biblia-online.pl/Biblia/Warszawska/Ewangelia-Jana/20/4A Piotr i Jan wstępowali do świątyni w godzinie modlitwy, o dziewiątejhttps://biblia-online.pl/Biblia/Warszawska/Dzieje-Apostolskie/3/1A gdy apostołowie w Jerozolimie usłyszeli, że Samaria przyjęła Słowo Boże, wysłali do nich Piotra i Janahttps://biblia-online.pl/Biblia/Warszawska/Dzieje-Apostolskie/8/14

You don't need to handle your inbox anymore. It's Cora's job now. Cora is the AI chief of staff we built for your email at Every. It's been in private beta for the last 6 months and currently manages email for 2,500 beta users—and today we're making it available for anyone to use. Start your free 7-day trial by going to: https://cora.computer/Cora is the $150K executive assistant that costs $15/month. Or $20/month if you want an Every subscription, too. This is what that actually means:Cora understands what's important to you, screens your inbox, and only lets the most relevant emails through. The rest of your emails are summarized in a beautifully designed brief that's sent to you twice a day.If it has enough context, Cora drafts replies for you in your voice.You can talk to Cora like you would your chief of staff—you can give it special instructions on how you want certain emails handled, ask it to summarize things, and even give you an opinion on complex decisions.In this episode of AI & I, I sat down with the team behind Cora—Brandon Gell, head of the product studio; Kieran Klaassen, Cora's general manager; and Nityesh Agarwal, engineer at Cora—for a closer look at how it all came together. We talk about:The story of the first time Brandon, Kieran, and I used Cora, while sipping wine at the Every retreat in Nice. The evolution of Cora's categorization system, from a 4-hour vibe-coded prototype to a multi-faceted product with thousands of happy users.The features on Cora's roadmap we're most excited about: a unified brief across different email accounts, an iOS app, and an even more powerful assistant.This is a must-watch if you're curious about what it feels like to give Cora your inbox, and take back your life. Go to https://cora.computer/ to start your 7-day free trial now.If you found this episode interesting, please like, subscribe, comment, and share! Want even more?Sign up for Every to unlock our ultimate guide to prompting ChatGPT here: https://every.ck.page/ultimate-guide-to-prompting-chatgpt. It's usually only for paying subscribers, but you can get it here for free.Sponsor: Experience high quality AI video generation with Google's most capable video model: Veo 3. Try it in the Gemini app at gemini.google with a Google AI Pro plan or get the highest access with the Ultra plan.To hear more from Dan Shipper:Subscribe to Every: https://every.to/subscribe Follow him on X: https://twitter.com/danshipper Timestamps:Introduction: 00:01:40Three ways Cora transforms your inbox (and your day): 00:04:21A live walkthrough of Cora's features: 00:05:09The inside story of the first time Kieran, Brandon, and Dan used Cora: 00:12:13Train Cora like you would a trusted chief of staff: 00:16:30The AI tools that blew our minds while building Cora: 00:27:25How we build workflows that compound with AI at Every: 00:30:34The dream features that we'd like to put on Cora's roadmap: 00:42:36Links to resources mentioned in the episode:Try Cora now with a 7-day free trial: https://cora.computer/ The episode about how Kieran and Nityesh use Claude Code to build Cora: "How Two Engineers Ship Like a Team of 15 With AI Agents" 

Sermon Scripture: Acts 2:1-21A long time ago, God made a promise. He said, “One day, I will pour out my Spirit on all people.” That means God wouldn't just be with a few special people anymore—he would be with everyone who wants him.On Pentecost we remember the first sermon, the first baptisms, and the beginning of the Church, but most of all, we remember that God kept his promise. And if God kept that promise, we can trust him to keep every other one too.

This was a clever Wednesday crossword, and not just because its author, Peter A. Collins, slipped 21A, Understanding, KEN, and 22D, Astuteness, ACUMEN, into the grid. It was, inevitably, the theme that made this crossword shine, and you'll discover the meta-joke in that assessment when listening to today's episode (or when you've solved the crossword, whichever comes first).Show note imagery: Members of the G6 - France, Germany, Italy, Poland, Spain, and the United KingdomWe love feedback! Send us a text...Contact Info:We love listener mail! Drop us a line, crosswordpodcast@icloud.com.Also, we're on FaceBook, so feel free to drop by there and strike up a conversation!

Straight Outta Context 6, Week 2Pastor Nathan Zickert · Mark 10:21A video recording of this sermon is available here.For more information about Grace Community Church of Riverside, visit us online at https://www.gccriverside.com.

21A los tres días había una boda en Caná de Galilea, y la madre de Jesús estaba allí. 2Jesús y sus discípulos estaban también invitados a la boda. 3Faltó el vino, y la madre de Jesús le dice: «No tienen vino». 4Jesús le dice: «Mujer, ¿qué tengo yo que ver contigo? Todavía no ha llegado mi hora». 5Su madre dice a los sirvientes: «Haced lo que él os diga». 6Había allí colocadas seis tinajas de piedra, para las purificaciones de los judíos, de unos cien litros cada una. 7Jesús les dice: «Llenad las tinajas de agua». Y las llenaron hasta arriba. 8Entonces les dice: «Sacad ahora y llevadlo al mayordomo». Ellos se lo llevaron. 9El mayordomo probó el agua convertida en vino sin saber de dónde venía (los sirvientes sí lo sabían, pues habían sacado el agua), y entonces llama al esposo 10y le dice: «Todo el mundo pone primero el vino bueno y, cuando ya están bebidos, el peor; tú, en cambio, has guardado el vino bueno hasta ahora». 11Este fue el primero de los signos que Jesús realizó en Caná de Galilea; así manifestó su gloria y sus discípulos creyeron en él. 12Después bajó a Cafarnaún con su madre y sus hermanos y sus discípulos, pero no se quedaron allí muchos días. 13Se acercaba la Pascua de los judíos y Jesús subió a Jerusalén. 14Y encontró en el templo a los vendedores de bueyes, ovejas y palomas, y a los cambistas sentados; y, 15haciendo un azote de cordeles, los echó a todos del templo, ovejas y bueyes; y a los cambistas les esparció las monedas y les volcó las mesas; 16y a los que vendían palomas les dijo: «Quitad esto de aquí: no convirtáis en un mercado la casa de mi Padre». 17

"God made him who had no sin to be sin for us, so that in him we might become the righteousness of God." - 2 Corinthians 5:21A visual learner? Watch the stream back now! Hosted on Acast. See acast.com/privacy for more information.

HOLD FIRMLY TO WHAT YOU ARE CONFESSING (NO WAVERING)JOSHUA 24:14-21A real Word from God by Pastor Randy.Hear the passion and the plea to receive Jesus as Savior and Lord before it is too late.You will be challenged and blessed. Beacons For Christ Ministry, UKOur mission is to be a Beacon of light to the world; spreading light, love and the gospel of Jesus Christ our Lord and Savior, through Kingdom works.Presiding Pastor: Rev. Randy LightbourneFirst Lady: Rev. Eunice Lightbourne.HOLD THE LINEBlessings Abound!

A rather curious THeme, Jean sussed it immediately, Mike aspires to do so at an indeterminate point in the hopefully near future.

Send us a Text Message.Don't bother looking for rebuses (rebusae)? in today's grid - there aren't any. But the theme that we have instead is still tricky and amusing, and we doff our hats in what we imagine to be the general direction of Mat Shelden, the author of today's fine work, a debut in the NYTimes. Show note imagery: PEETA, who, according to 21A, is Katniss's partner in "The Hunger Games"Contact Info:We love listener mail! Drop us a line, crosswordpodcast@icloud.com.Also, we're on FaceBook, so feel free to drop by there and strike up a conversation!

Sunday Morning, May 26, 2024Watch Out for Substitutes ... 1 John 5:21A message delivered by Pastor, Richard Fleming

¿Cuáles son los puntos donde creemos que tiene que haber más énfasis en el cubrimiento de las marchas que se convocan y se realizan en contra del Gobierno de Gustavo Petro?Producción: Sara TrejosEquipo: María Paula Martínez, Andrés PáramoPost: Rodrigo RodriguezAsistencia: Paula VillánEquipo Donaciones: Jenniffer AbaunzaSillón Estudios 2024.NOTASTerapia de pareja entre el Petrismo y a la oposición I A FONDOEl constituyente primario que protestaCalma, señor presidente; escuche y reflexioneJuicio político: el pedido al Congreso contra Petro que se “coló” a la marcha I La Silla VacíaLos protagonistas del 21A fueron más que la derecha I HUEVOS REVUELTOS Debate: Si marchas del 21 de abril son masivas, ¿cuál sería el mensaje para Petro? I WRADIOMasiva marcha de colombianos contra Petro: ¿los escuchará el presidente? I CARACOL NOTICIASPetro dice que marchas en su contra “fueron débiles”. Aunque solo en Medellín salieron 350 mil personas, presidente asegura que asistieron 250 mil en todo el país I SEMANATras marchas, presidente Petro insiste en un 'golpe blando' contra su gobierno I PORTAFOLIOPetro se burló de las marchas tildándolas de “clase dominante”, mientras su escudera Sarabia llamó a la reflexión del Gobierno I EL COLOMBIANOManifestantes agredieron a periodistas de RTVC y El Tiempo en marcha contra Petro en Barranquilla I PUBLIMETROCiudadanos comparan marcha en contra del presidente Gustavo Petro con la que se hizo en 2008 para reclamarle a las Farc I SEMANA Get bonus content on Patreon Hosted on Acast. See acast.com/privacy for more information.

Federico analiza los errores de la campaña del 21A del PP con Carlos Cuesta y Tomás Cuesta. Entrevista sobre Otegi: La última bala de ETA.

Federico analiza los errores de la campaña del 21A del PP con Carlos Cuesta y Tomás Cuesta. Entrevista sobre Otegi: La última bala de ETA.

Dr. Adam Striker welcomes Dr. Vaibhav Bora, member of the ACE editorial board, to the show to discuss GLP-1 Agonists, a topic that appears in the 21A issue. The conversation touches on mechanisms of action, brand names, how these agents interact with insulin, side effects, guidelines, and more. Recorded March 2024

Carlos Alsina reflexiona en su monólogo sobre la próxima cita con las urnas para las elecciones vascas del domingo 21 de abril. Una campaña electoral que PNV y Bildu afrontan muy igualados, a decir de los sondeos, y en la que el PSE será clave.

Mark 8:1-21A community transformed by grace sent to transform the world for the glory of God.WEBSITE: https://c3lr.orgFACEBOOK: facebook.com/C3.LittleRockINSTAGRAM: instagram.com/c3.littlerockSERMON PODCAST:  https://c3littlerock.buzzsprout.com

Sunday Morning, March 17, 2024Series: Living with Certainty in an Uncertain World Perfect Love ... 1 John 4:15-21A message delivered by Pastor, Richard Fleming

Scott Bogman and Pat Fitzmaurice run through the early consensus 2024 dynasty wide receiver rankings. Throughout the show, they discuss whether Jameson Williams is still a worthy investment, talk about why it's so hard to rank Zay Flowers, and share their thoughts on how concerned they'd be if Rashee Rice ends up being the Chiefs' No. 3 receiver. Timestamps:Introduction - 0:00:00S Tier - 0:02:08CeeDee Lamb - 0:02:21A.J. Brown - 0:03:58Tyreek Hill - 0:04:33A Tier - 0:06:01Puka Nacua - 0:07:14Marvin Harrison Jr. - 0:09:08Enter the Perfect Draft Challenge - 0:10:23B Tier - 0:11:38DeVonta Smith - 0:11:57DJ Moore - 0:13:17Zay Flowers - 0:16:01DK Metcalf - 0:18:21Brandon Aiyuk - 0:20:03Rashee Rice - 0:21:32C Tier - 0:24:24Jaxon Smith-Njigba - 0:24:41Tank Dell - 0:26:36Jordan Addison/Cooper Kupp - 0:29:16D Tier - 0:32:32George Pickens - 0:33:03Christian Watson - 0:36:40Jahan Dotson - 0:39:25F Tier - 0:41:29Jameson Williams - 0:41:54Quentin Johnston/Elijah Moore - 0:44:21Who are we done with? - 0:47:36Mike Williams - 0:48:53Romeo Doubs - 0:50:10Demario Douglas - 0:52:022024 Dynasty Rookie Class - 0:53:01 Helpful Links:Take Part in Our Perfect Draft Challenge! - With the Perfect Draft Challenge, you can go back in time, draft against our simulated opponents, and try to nail the perfect draft for the 2023 season. Invite your friends and compete on our community leaderboards to see how you stack up. Drafts are free and take just 5-10 minutes - https://www.fantasypros.com/perfectdraft/ Leave a Review – If you enjoy our show and find our insight to be valuable, we'd love to hear from you! Your reviews fuel our passion and help us tailor content specifically for YOU. Head to Apple Podcasts, Spotify, or wherever else you get your podcasts and leave an honest review. Let's make this show the ultimate destination for fantasy football enthusiasts like us. Thank you for watching and for showing your support. BettingPros Podcast – For advice on the best picks and props across both the NFL and college football each and every week, check out the BettingPros Podcast at bettingpros.com/podcast, our BettingPros YouTube channel at youtube.com/bettingpros, or wherever you listen to podcasts.See omnystudio.com/listener for privacy information.

It is not clear how many Zoom calls Esha Datta, author of today's crossword (her debut!) has been in, but we're willing to bet LOADS of them, based on their (very clever) theme. Beyond that, there were numerous notable clues, from 21A, Only country with a non-rectangular flag, NEPAL (maybe: checkout the podcast for a rebuttal); 37D, Notable lamb owner, MARY (as clues go, this one's not baaaaaad

A fine Friday crossword by Adrian Johnson, his 5th NYTimes Crossword contribution. Considering that 39A, Pub ________, TRIVIA, was one of the answers, it should not be surprising that quite a few factoids made their way into the grid. For example ... 19A, Novelist whose "Little Fires Everywhere" became a #1 best seller, CELESTENG (parsed as Celeste Ng, with the "Ng" being pronounced as "ing"). We also had 21A, Bird whose largest species is called the Goliath. HERON; and 46A, Romanian philosopher Cioran, EMIL. For our Fun Fact Friday / Listener Mail Double-Dipping special, we also have a fascinating video of Justin Bieber's early drumming attempts.Contact Info:We love listener mail! Drop us a line, crosswordpodcast@icloud.com.Also, we're on FaceBook, so feel free to drop by there and strike up a conversation!

Shaun O'Sullivan from the 21st Amendment Brewery is back on The Session to discuss the latest at 21A and the state of the industry. Shaun and his business partner Nico Freccia have grown 21A from its beginnings as a neighborhood brewpub in San Francisco to a regional brewery with national distribution. Along the way Shaun has seen many changes in the industry and gives his insight here into where things are headed. Learn more about your ad choices. Visit megaphone.fm/adchoices

Scripture: Romans 12:9-21A letter to the early church offers and inspiring—then challenging—instruction on how to hold together in community after rupture and conflict, and maybe after we have been… wild things. The post Loving and Leaving Room appeared first on Foreside Community Church.

Romans 5: 15-21A continued study through the book of Romans. In part four of this week's series we saw Christ's sufficiency over the law. Today we look at why grace is sufficient! Christ and faith in His completed work is the only way to God and His grace is sufficient for EVERY sin. 

What does it take to lead a health department with a budget of more than $50 billion, overseeing the health of nearly 20 million Americans? Here to tell us about that is Dr. Nirav R. Shah, who was the 15th New York State Commissioner of Health from 2011 to 2014. Today, Dr. Shah is a nationally recognized advocate of patient safety, health care innovation, and high-quality, low-cost care. He has variously served as Chief Operating Officer of Kaiser Permanente in Southern California, Advisor to the CDC Director, Senior Fellow of the Institute of Health Improvement, and Senior Scholar at Stanford University's Clinical Excellence Research Center. In this episode, Dr. Shah joins us to share his philosophy of healthcare leadership and how meaningful relationships anchor his work.In this episode, you will hear about:How Dr. Shah's upbringing and the influence of Jainism steered him away from a lucrative career in finance and into medicine - 1:53Two patient stories in which seemingly simple mistakes led to moments of awakening for Dr. Shah in recognizing his purpose in medicine - 6:21A brief overview of Dr. Shah's career path - 13:47Lessons on empathetic leadership that Dr. Shah picked up along the way - 19:21How forging strong relationships helped Dr. Shah find solutions on big issues during his time as New York State's Health Commissioner - 21:57Dr. Shah's current pursuits, including those focused on making a business case for supporting the unpaid caregivers of patients - 31:23Why transparency and bureaucratic structure are critical components of healthcare reform in the United States - 37:46Advice to clinicians on what makes effective leaders and collaborators, and how to find passion for meaningful projects - 41:43Dr. Shah is a trustee of the John A. Hartford Foundation, a board member of STERIS, and an advisor to GSR Ventures.You can follow Dr. Nirav R. Shah on Twitter @NiravRShah or on LinkedIn.Visit our website www.TheDoctorsArt.com where you can find transcripts of all episodes.If you enjoyed this episode, please subscribe, rate, and review our show, available for free on Spotify, Apple Podcasts, or wherever you get your podcasts. If you know of a doctor, patient, or anyone working in health care who would love to explore meaning in medicine with us on the show, feel free to leave a suggestion in the comments or send an email to info@thedoctorsart.com.Copyright The Doctor's Art Podcast 2023

Brendan Emmett Quigley has crafted an elegantly enjoyable Friday crossword -- clues that are brilliant (54A, One who is mean as the Dickens?, SCROOGE), enlightening (15A, Whom the New York Times co-named athlete of the year, with Babe Ruth, in 1920), MANOWAR, and impossible to spell (21A, Missed-the-turn maneuver, UEY). We liked this crossword ATON, THATSFORSURE; and to find out precisely why, just tap Subscribe / Download / Play / Enjoy (um, if you do find the Enjoy button, do let us know

A relatively straightforward Friday crossword, with some elegant subtleties in the grid that need to be seen to be appreciated. For instance, let us draw your attention to the intersection of 54A, Response to someone who got the answer instantly, YOUNAILEDIT, and 36D, Crushed a test, ACEDIT. [That was apparently the section of the grid devoted to smarties.] We also had 21A, _____ blanc, VIN, and 45A, _____ noire, BETE (where blanc is white and noire is black, in French). Finally we had 28A, Fictional weapon of the 23rd century, PHASER, and 9D, More, on a score, PIU, which is, as all good Trekkies know, the sound that a PHASER makes, as in PIU, PIU, PIU.For Fun Fact Friday, we had a listener, and a soon-to-be-published crossword constructor (!)  email us our fun fact for the day, so be sure and tune into that as well.

A nice Friday crossword by a veteran constructor, Robyn Weintraub. Jean found the puzzle to be a piece of cake, Mike found it to be almost impossible, until the crossword deities smiled benevolently upon him, and reminded him that a better answer for 21A, Employment history, would be CAREER, rather than RESUME or CRVITA. Robyn is known for her great clues, and today's puzzle is exemplary. In other news, it's Fun Fact Friday, and today' we explore the mysterious life and times of ENOS, chimp in space!

There are good employees and there are excellent employees. There are also those employees you know aren't performing well enough to stay or progress in your company. But to begin with, on what basis do you assess your employees' performance? What makes a five-star employee? Does a two-star employee have to stay a two-star employee? How can they grow themselves? Find answers to all those questions in this episode of the Advance podcast with Mike and his guest Danielle Mulvey. Danielle reveals the ingredients that make a five-star employee – the irreplaceable one who delivers consistent results for the company. With 25 years of experience as an entrepreneur, Danielle comes equipped with all the knowledge regarding hiring the right people for your team, letting go of those employees who don't fit well, and the metrics to assess each of them for their skills, ability, and performance. She also shares how she does the market analysis and competition to provide adequate pay to her employees. Listen in! EPISODE 19  SUMMARY & HIGHLIGHTS What is the biggest mistake entrepreneurs make when hiring their first few significant hires? 1:33 They take everything that they don't want to do, or they're not good at, and assign it to the new hire. The problem is, often, it becomes too much for the other person. What is a five-star employee? 9:18 A five-star employee represents the top 15% of available talent in the market for the role. A major hiring mistake made by businesses is not casting a very wide net for applicants. Hiring from a small pool means your chances of getting that 5-star employee are also less.Does a two-star employee always have to be a two-star employee?19:21A two-star employee is two-star only for that role. Danielle and her team have identified 11 Universal qualities that are key to being a five-star employee – some are coded red, which means they're very difficult to change, two are coded green, and the rest are coded gray. The green ones are relatively easy to change, and the gray ones also can be changed, but maybe with some coaching or help from a hiring manager. The red ones are the toughest to change.How much time should we give employees to improve their performance before they're shown the door?24:20In the shortest, possibly two weeks. Also, we don't need it to take six months. The reason is, we're all creatures of comfort. If we can show up to a place and the people there are relatively polite to us, and we get a paycheck every other week, we'll stay within that comfort zone forever. To a certain degree, you have to make it a bit uncomfortable for those employees so they're ready to move on and can move on quickly.(Full shownotes at https://connect.stepstoadvance.com)

An ingenious theme in today's crossword, an anti-rebus -- instead of multiple letters scrunched into one square, we have two letters expanding out of ... nothing, just like the Big Bang (although not quite as noisy). Today's crossword was by Jeff Chen, and that means quality. Clues like 38A, One of two in 2/22/22, SLASH, and the amazing (and debut word)  21A, Carnivorous : meat :: carpophagous : ________, FRUIT are just a few of the many Easter eggs that await the diligent spelunker of today's grid.

Originally Aired 8/12/21A talented teacher and performer, Jessica Antes(Second City, She Camp) stops by to share her love of a Mezcal Margarita! She recalls sharing her sister's Hooch, watching classic movies, and a blue-eyed hunk.  #NotRob gets a sugar mama and Josh gets touched by evil. Water GodJess aka Smoldering Antes2 oz Mezcal2 oz Watermelon  Juice1 oz Lemon Juice.5 oz of elderflower liqueurOptional agave syrup

A delightful Sunday puzzle by Daniel Mauer, a nostalgic trip along THEMOTHERROAD, (21A, Nickname for ROUTESIXTYSIX coined by John Steinbeck). While Mike had scarcely heard of the thing, Jean lived right *by* it, and so will be your expert tour guide in our exploration of today's theme. Subscribe, download, enjoy!

A fine Wednesday crossword by Alex Bajcz, and if you like pinball games, doubly so. There was much to like in today's grid, with fun clues like 1A, One inclined to go in and out, RAMP (nice!); 31D, Drollery, WIT (drollery, truly one of the great words of the ... 17th century?); and of course 21A, County north of the Firth of Forth, FIFE (of course it is). So hat's off to today's constructor, we give this a 5 squares on the JAMCR scale.

Though there's widespread consensus that the slavery and colonization that characterize the history of European relations with Africa represent a legacy of grave injustice, there is much less agreement on how to redress that injustice. Professor M. Amah Edoh, who teaches in MIT's Department of Anthropology, designed the course 21A.S01 Reparations for Slavery and Colonization with the goal of honestly facing the historical record and openly discussing how best to respond. Because she believes expertise is too often conceived of as something that flows “north-south” from the developed nations toward the developing world, she structured the course to embrace expertise wherever it might be found—recruiting guest lecturers from various disciplines and from institutions around the world, as well as activists currently involved in the quest for reparative justice. She even went a step further, sharing the lecture videos on YouTube while the semester was still ongoing and inviting viewers to contribute their own insights into how to deal with the ongoing legacy of historical wrongs. In this episode, Prof. Edoh describes the motivation for this innovative course structure and reflects on the challenges of grappling with such a sensitive subject.Relevant Resources:MIT OpenCourseWareThe OCW Educator PortalShare your teaching insightsProfessor Edoh's faculty pageCourse materials by Professor Edoh on OCW21A.S01 Reparations for Slavery and ColonizationOpen Learning story on 21A.S01OCW YouTube playlist for 21A.S01Africa's Expertise (YouTube lecture by Prof Edoh)African Futures Action LabHow Africa Has Been Made to Mean (2020 episode of Chalk Radio)Music in this episode by Blue Dot Sessions Connect with UsIf you have a suggestion for a new episode or have used OCW to change your life or those of others, tell us your story. We'd love to hear from you! Call us @ 617-715-2517On our siteOn FacebookOn TwitterOn Instagram Stay CurrentSubscribe to the free monthly "MIT OpenCourseWare Update" e-newsletter. Support OCWIf you like Chalk Radio and OpenCourseware, donate to help keep these programs going! CreditsSarah Hansen, host and producer (https://twitter.com/learning_sarah)Brett Paci, producer  (https://twitter.com/Brett_Paci)Dave Lishansky, producer (https://twitter.com/DaveResonates)Show notes by Peter Chipman

Are you thinking of moving from the restaurant business to the real estate business? Jeremy Cisneros did just that. He went from owning a McDonald's franchise to investing in the multifamily space. He joins our podcast to share his insights on operating and optimizing businesses and how he's able to wear different hats in real estate with his experience as a lender, underwriter, and investor.   [00:01 - 07:24] From McDonald's to Multifamily Why Jeremy made the move to multifamily Bringing his restaurant experience to real estate Managing and developing people and processes Looking at things on a weekly basis   [07:25 - 11:22] Scaling a Multifamily Business Jeremy reveals how he and his group sourced 1200 deals The importance of having the right partner and processes Don't waste time with the wrong deals Empowering and giving autonomy to your deal team   [11:23 - 14:50] Employing His Lender Skillset Here are lessons he learned from being a lender Common misestimations people make in deals Building relationships goes a long way   [14:51 - 15:49] Closing Segment Reach out to Jeremy!  Links Below Final Words Tweetable Quotes “...there's many years of long days and hours to, you know, see how an operation works together and get more efficient. It's just kind of taking those learned skills from people and working in developing those individuals to bring that into what we do today.”  - Jeremy Cisneros   “... having a borrower's hat in the lender's hat, I know that when I'm presenting something to a lender, you got to be a little bit more aggressive to get the proceeds you want. So I get it. It's a back and forth game.” - Jeremey Cisneros   -----------------------------------------------------------------------------   Connect with Jeremy though https://www.symphonycapitalgroup.com/ and https://www.thegrowthvue.com/.    Connect with me: I love helping others place money outside of traditional investments that both diversify a strategy and provide solid predictable returns.   Facebook LinkedIn   Like, subscribe, and leave us a review on Apple Podcasts, Spotify, Google Podcasts, or whatever platform you listen on.  Thank you for tuning in! Email me → sam@brickeninvestmentgroup.com   Want to read the full show notes of the episode? Check it out below:   Jeremy Cisneros  00:00 We're not just looking to raise capital, we are looking to provide and leverage some of our real-world asset management. So that's one group. And then the other group I work with is called Growth Vue Properties. And we are really a deal finder sourcing... I think last year, we sourced almost 1200 deals 100 plus a month, we have a good team and process in place. And, you know, we've been able to partner with some large equity groups and capital partners to take these deals down. So we're doing things a little differently on those two respects, but it's been a tremendous ride.   Intro  00:30 Welcome to the How to Scale Commercial Real Estate Show. Whether you are an active or passive investor, we'll teach you how to scale your real estate investing business into something big.   Sam Wilson  00:42 Jeremy Cisneros, a McDonald's owner-operator turned multifamily investor. His hands-on experience in turning around and optimizing businesses from top to bottom really helped him out in the multifamily space. Jeremy, welcome to the show.   Jeremy Cisneros  00:54 Thanks so much for having me on, Sam. Excited to be here. And looking forward to it.   Sam Wilson  00:57 Hey, man, the pleasure is mine. There's three questions I ask every guest who comes on the show. In 90 seconds or less, can you tell me where did you start? Where are you now? And how did you get there?   Jeremy Cisneros  01:06 Yeah, so I started in the residential space similar to a lot of folks. I got my license as soon as I got to California from New York, originally background in McDonald's franchise owner, operating. And today we're in multifamily investing, passively along the way, and then eventually became into the active space. So here we are today. And yeah, I'm sure we'll dive in a little bit deeper.   Sam Wilson  01:28 That's really fascinating. So you own McDonald's franchises. But how many restaurants did you own?    Jeremy Cisneros  01:35 We own seven in midtown Manhattan and the Upper East Side. So my father kind of scaled that up over the course of his almost 30-year career, and I was in it five years there before we sold.   Sam Wilson  01:45 Gotcha. Okay, so you guys have divested of those? Can you walk us through, I guess the thinking behind selling off a McDonald's franchise, it seems like those would be, one, hard to come by and, two, valuable assets to own.   Jeremy Cisneros  01:57 Definitely, the goal was to scale long term, but the overarching reasons of just squeezing profit margins, and increasing costs, etc. And then being in the environment of New York City, you have to pay the taxes as a franchise owner. Real estate taxes are really expensive. And what we saw was just long-term, wanted to divest. And so we had an opportunity. One of our locations sat on a very valuable piece of dirt over the Hudson Yards project on the west side of Manhattan. The developer approached us and then approached the corporation on the land. We own the lease up until 2022. So they bought us out of our lease, and they bought the land and we sold the other six locations to another operator.   Sam Wilson  02:37 Gotcha. And it was at that point, you said, “Hey, I'm going multifamily,” or did you already have your hands in multifamily before then?   Jeremy Cisneros  02:43 I wish I had, you know, I spent a few years in residential. Nothing wrong with that. It was a great experience. I was a realtor, as I mentioned, just kind of working with buyers and sellers, but then multifamily, probably two or three years after that, and have been really just kind of obsessed since.   Sam Wilson  02:59 What are some things that you've learned are some things that you feel like you've brought from the restaurant slash franchise space that you bring into the multifamily investing space? That gives you a competitive edge, I guess, is the question I'm asking, over what you see other people doing.   Jeremy Cisneros  03:14 I'm an underwriter by background, I've done a lot of lending. So that has helped him kind of rounded out my operational experience that I had, working physically in the trenches at McDonald's from the back office, looking at P&L and our balance sheets on a daily weekly basis, has been really helpful to really optimize the revenue, and then fine-tune the expenses without really like crippling the payroll, at the end of the day. You understand what it's like working shoulder to shoulder with those who are actually performing what comes out on that store-operating income or net operating income, as we're familiar with in real estate, what it actually takes in the day to day working long hours. I can empathize and I definitely able to, I think now, there's many years of long days and hours to, you know, see how an operation works together and get more efficient. It's just kind of taking those learned skills from people and working in developing those individuals to bring that into what we do today.   Sam Wilson  04:06 When you say developing those individuals, what are some thoughts that come to mind?   Jeremy Cisneros  04:10 We're not vertically integrated at the moment. And you know, I love people, sometimes a gift and a curse to manage a whole team. We have 350 employees across our locations, and individual stores, you know, it's just a lot of personalities and characters. And I think a big control aspect of owning multifamily is owning your own management company as well. So what we do as asset managers, we oversee the property managers who are professionals in those designated markets, and we're just really talking with the regional managers, just making sure we're aligned with our core visions and core values as we kind of set those up in my companies through a known system Entrepreneurial Operating System that I've now implemented from one business to the next.   Sam Wilson  04:51 Yeah, and I think you're referring to EOS system in Traction.    Jeremy Cisneros  04:55 You know, like, Wickman, yep.    Sam Wilson  04:56 Wickman, there you go. That's who it is. Yeah, that's really intriguing. Tell me about when you manage those people and those processes, I guess, what are some things that you look for, especially in your property management side? Maybe again, you're coming at this from a different angle than what a lot of us may be coming into the industry from, do you feel like there's things you see differently?   Jeremy Cisneros  05:06 I think each asset is different. You know, again, I looked at the numbers pretty regularly, I think conditioned to look at things on a weekly basis. And my father is a big proponent of what gets measured gets done. So we just make sure we're looking at things on a micro-level, and making sure that we're just optimizing as much as possible, you know, we want to be as fair and transparent with our tenants who are maybe looking for a better living experience and community. So we're happy to provide something like that at a reasonable cost. We think at the end of the day, and then seeing what's working with renovation turns, improving the communities, the amenities, just deferred maintenance, and all that. Not everything is a heavy revenue driver, but the experience can help reduce turnover and sometimes unforeseen expense at the end of the day, when you're looking at your bottom line. It's not something that you can quite measure. But the less turnover, you have, the obviously more profitable you're going to be.   Sam Wilson  06:09 What are some of the things on a weekly basis, some snapshot items that you look at? Maybe that you say, “Hey, this tells us where we are.” And you can look at it in one minute and get kind of the health or state of the union for each property? Are there you know, five things you look at for each property? Or what is that?   Jeremy Cisneros  06:25 Yeah, typically, when we're doing our renovation plan, it's a little bit different than looking at more of a stabilized asset. So a lot of our deals have been more of a value-add plan. So we're sort of like net neutral from a cash flow perspective. But if I see things dipping below that debt service coverage ratio of like 0.10, I'll start to fine-tune and see like what's going on. Sometimes you just have, you know, leaky toilets, at the end of the day, it could be something as miniscule as that just flushing money down the drain, you know, no pun intended, and you don't realize it a few months go by and you're like, oh, wow, this line item has increased with technology, it's pretty easy to kind of catch upfront. So things like that. Obviously, tenants are all different. And they all pay at different moments in the month, we wish everyone paying on time. But it's not everyone's circumstance. So I think looking at things weekly, and then checking in on different revenue in different expense items, kind of those two small examples I gave are definitely what we try to keep our on site property managers looking at and kind of training them to look at these things without the help of us in the long run.   Sam Wilson  07:25 Yeah, I love that. How have you scaled your multifamily business, what has been your preferred approach?   Jeremy Cisneros  07:33 So I work with two groups Symphony Capital. So we do a lot of partnerships, our co-general partnership, as it come in the syndication world, we have really scaled our deal flow, when we have partners who are in contract, and we'll bring some capital, we also bring some of that asset management experience. We're not just looking to raise capital, we are looking to provide and leverage some of our real-world asset management. So that's one group and the other group I work with is called Growth Vue Properties. And we really deal finder sourcing... I think, last year, we sourced almost 1200 deals, 100 plus a month, we have a good team and process in place. And you know, we've been able to partner with some large equity groups and capital partners to take these deals down. So we're doing things a little differently on those two respects. But it's been a tremendous ride thus far.   Sam Wilson  08:20 Source 1200 deals, that's a lot of deals is that 1200 That you underwrote? And then you know, 120 of those you took a second look at or is that 1200 That you underwrote and said, “Hey, here's deals that we feel we could move forward on.   Jeremy Cisneros  08:34 Our team is not that big just yet. Those were the ones that hit the inbox. We took our first plan was we go through our neighborhood screen because we'd like to be at least 30 to 45 minutes with an MSA of 500,000 plus. And if it fits that we then use neighborhood scout and a few other tools to fine-tune, hey, does this neighborhood got good job growth, median household income, decent crime in schools. And then if it fits those boxes, we'll go to our pre-underwrite phase, if it checks a few boxes, then we'll go to a full underwrite phase. And that's where I pick it up from there. You know, it takes time, but we've really developed this efficient, streamlined process now.   Sam Wilson  09:08 I want to spend a little time here because this is really I think, interesting. What is your final objective through Growth Vue Properties? I mean, is it to take it down yourselves? Is it to present a deal to an operating partner and say, “Hey, guys, you know, we want to share the deal. But now you guys take it and run it.” What's the objective there?    Jeremy Cisneros  09:24 Yeah, Growth Vue Properties, we like to be the lead syndicator and sponsor on a deal. And then we have a great, like I said, partner within the capital space who's just looking to get more multifamily deals. So they're more of a self-storage investor historically and are kind of pivoting in this direction. So we would still obtain the asset management going forward and work directly with the property manager. And we're, you know, in a couple of markets now.   Sam Wilson  09:48 Okay. These are deals that you guys want to take down yourselves and hold in-house. It sounds like you've structured a creative finance partner for it.   Jeremy Cisneros  09:56 Yeah, I've been very fortunate that my partner, Samson, has got some great partners, tips and ways of building teams that's has been his background. And now that we've kind of put a couple years into building this process and this engine and system, it's starting to pay some dividends.   Sam Wilson  10:09 That's interesting. 1200 deals, that's a lot to take passes, or at least even just to look at, I mean, it's a lot of emails and say, “Hey–    Jeremy Cisneros  10:17 It's a lot.    Sam Wilson  10:17 Yeah, how have you made it easy, where you don't spend too much time looking at the wrong deals?   Jeremy Cisneros  10:23 That's a great question. A lot of time could be spent looking at bad deals. So our team that has kind of scaled to about five or six folks now specifically, just on the deal team, our training and just looking at so many deals repetitively, they know to pass or kill more deals than they are letting through because and when we empower them, we give them the autonomy to do so. If they're something on a line where this prime is okay, but the income looks good. We'll talk those through and work on them as a team. But yeah, you can end up spinning your wheels on these deals that are just at first blush should have been removed for preliminary reason.   Sam Wilson  10:56 Right? And have you done that primarily with virtual assistants? Or is these people you've brought it in-house? What's that team look like?   Jeremy Cisneros  11:04 Definitely like to leverage VAs, but all of our employees so far have been interns or equity members. That's kind of like I said, Samson has been a great connector there, of bringing in folks that he's known from previous experiences. And they've been tremendous. So all local, either Colorado, I live in San Diego. So that's where our two hubs are at the moment.   Sam Wilson  11:23 Gotcha. That's awesome. Okay. Very cool. Talk to us a little bit about your lending background. I know, you said you came in, you did some brokerage work. And then you did some lending. How does that play into your current business? And I guess, what skill sets did you obtain while doing lending that you employ currently?   Jeremy Cisneros  11:39 Yeah, so I was specifically in the commercial real estate lending space at a regional bank. My group did loans from $20 to $150 million, our average travels is about $50 million. So these were good-sized, typically ground-up development deals. And it was a different structure. Usually, we were the senior analyst, and we worked with the debt fund that would provide the whole loan and boost their return, very interesting structure. But what I learned going through that whole process was I brought the deal in from the broker or the borrower directly, and I worked on it through the whole process to close it. It wasn't set up where you bring it in as a sales team. And then you kind of get it through the credit committee, and then you pass it off. And the deal, you know, the underwriting team closes it, the structure here was very flat, if you broaden the deal, you closed it. And then oftentimes, it stays on your books, and you also help manage the deal too, after you've closed it. It's a great experience. And those few years, I feel like it was there for six years rather than three years. And it was just a tremendous experience, many hours reminded me of like a New York firm that I worked for. And that whole time there, it was just learning how to use your lender hat, doing work conservative, because the credit committee would typically slash rents, they would reduce expenses for both the borrowers or… and come to a happy medium att the end of the day. I think I used those skills today in my underwriting.   Sam Wilson  12:56 What are some things you saw commonly when deals were sent to you that you guys went back to you and said, “No,” you know, like you said, raise expenses, cut rents, anything else that comes to mind that you said that you saw people were commonly misestimating?   Jeremy Cisneros  13:11 Yeah, a lot of our deals came through New York borrowers specifically multifamily. So these would be deals that would have tax abatements for 21A, specifically in that market. So we would just verify it through lenders and counselors that we had locally in the New York market, we'd also just always have to double-check the buildable square feet, the FAR, the floor area ratio just based because everything in New York is vertical in the city. So you know, whether you're able to build to a 3 FAR or a 10 FAR is gonna make all the difference as an air rights. So it got pretty complex. I don't particularly acquire in New York City, I have some colleagues that do. And that's a whole other can of worms considering when New York's going through. But I'd like to think that in the future, we'll help because I would love to get into development in the future. So I think that kind of helps. And just now having a borrower's hat in the lender's hat, I know that when I'm presenting something to a lender, you got to be a little bit more aggressive to get the proceeds you want. So I get it. It's a back and forth game. It's a little bit of negotiating. At the end of the day, we try to build relationships long term with specific lenders.   Sam Wilson  14:15 Yeah, I think that's a great point, you know, and that's something that many have come on here and said as it pertains to lenders, as it pertains to insurance brokers, whoever it is, like, these are long term relationships. It's not, oh, thanks for the loan. I'm gonna go shopping again, with 20 other people on the next deal.   Jeremy Cisneros  14:31 We get that a lot. And the people that kept coming back and borrowing from us, we had great relationships and we were able to be flexible, what we were able to provide up to maybe a couple more dollars or reduced the rate a little bit. We weren't the cheapest lender. We're primarily just bridge lenders, construction lenders, but relationships went a long way.   Sam Wilson  14:51 That's fantastic. Jeremy, thanks for your time today. It's been fun learning about your history there in the McDonald's industry all the way to multifamily and how you guys have grown and scaled your company. Certainly appreciate it. If our listeners want to get in touch with you or learn more about you, what is the best way to do that?   Jeremy Cisneros  15:07 I appreciate the time, Sam, has been awesome. Like I said, I'm affiliated with two groups, symphonycapital.com, or thegrowthvue, that's VUE, .com. And feel free to reach out. I'm always open to have a quick conversation with anyone who's interested.   Sam Wilson  15:22 Jeremy, thanks so much. Have a great rest of your day. Appreciate it.   Jeremy Cisneros  15:24 You too, Sam.   Sam Wilson  15:25 Hey, thanks for listening to the How to Scale Commercial Real Estate Podcast. If you can do me a favor and subscribe and leave us a review on Apple Podcasts, Spotify, Google Podcasts, whatever platform it is you use to listen, if you can do that for us, that would be a fantastic help to the show. It helps us both attract new listeners as well as rank higher on those directories so appreciate you listening. Thanks so much and hope to catch you on the next episode.

C my creation? Do you see my word thought and deed? Do you C? Do you C? Do you C? Do you see? What do you See? A ghost of an intention? It's a trinity. We can build trust and safety and actualize Maslows hierarchy of need. Who woke this ghost? Was that the intention at conception?Follow me down my rabbit hole if you dare. I'm a true nobody which makes me an everybody. I see you and your core wounding (gift) because it's mine too... And also your highest potential (gift)…. Because it's mine too….We are starting from ground zero, let's make all the mistakes and correct them together. Solutions. Because… you guys…WE is so fucking powerful when it's well-intentioned , nonviolent and we have a+b=c then we  we begin to take off ( drone energy, is that built like a helicopter? My Dad did something with helicopters…Is my Dad going to fly in to save me or am I to bring you to Him?..  I don't get it. Wait if we mirror the triangle and flip it, we have 2 right triangles and he gives us 2 more that's four. Hmm.If we put them in all four quadrants, we have our wings.helicopter wings… Who needs wheels? Dads just raising me up, He took away my ankles and He is giving me my angle wings. Thank you so very much, I am humbled. I'm happy I got my angle wings back, I think God heard my prayer.. I always wanted to be a Fly Girl. When I was younger, I loved to dance.We just have to allow each other to stumble…and fumble…and tuck our skirt into the backs of our pantyhose….every now and again.This is a tower moment … only NOT of destruction, but of construction. And I have no game plan… join me on Patreon.  At Patreon sign up for the minimum price. Don't! Pay more than 5$ a month. You won't get anything extra. If 5$ makes you strapped, let me know and I'll see if we can find you someone who will sponsor you anonymously. Give me some time to get us off the ground. I work full time and then some.Alright I guess. Is that why I'm keeping 3 and 4 for me? Because we haven't balanced the Holy Trinity we haven't created stability? (4 of wands)We start at the root chakra, present day. I'm nobody and if you are too….. You're my kinda people.Hmm. I catapulted straight arrow up ascension, rocked back and forth pendulum energy, did a fancy little boomerang number and then I supernova'ed. if I didn't know any better, I'd think,  I was conceived. I know I was conceived in love.Arrow, bullseye..I made it to the circle, the inner circle. I hit the target. Wait, I saw Cupid in my minds eye… when was that? Let's see if I wrote it down… 12/14/21A couple of days ago I saw Cupid draw their bow…I think it might have landed …… did it land on WE? 12/12?I do everything in the Shadows, I'm extremely reserved and introverted, He had to coax me into the Light. And now He just put me Center Stage in my own life. I want Hailey to come back in the studio and read her writing.. aren't you sick of listening to me me me me me? I am. I need a fresh perspective.